


ISHL

11

**COLOGNE
GERMANY**



OCTOBER
27-29, 2018

FINAL
PROGRAM

GHSG
www.ghsq.org



Saturday (27.10.2018)	Sunday (28.10.2018)	Monday (29.10.2018)
07:30	07:30 – 09:00 Interactive Case Discussion (Faculty: M. Hertzberg, A. Lister / Presenters: D. A. Eichenauer, J. Romejko-Jarosinska, O. Baiocchi, S. Borchmann)	07:30 – 09:00 Advanced Stages (V. Diehl, P. Johnson) • ECHOLON1 Update (J. Radford) • HD18 Update (P. Borchmann) • LYSA AHL2011 Phase III Study (O. Casasnovas) • Oral Abstract Presentations
09:00	Coffee Break	Coffee Break
09:15	09:15 – 10:15 Oncology Meets Autoimmunity by Chugai (A. Engert) • Autotransplant in systemic sclerosis (J. Henes) • Autoimmunity in chronic GVHD (D. Wolff)	09:15 – 10:15 CAR T Cell Therapies: Hype or Hope? by Celgene (H. Einsele) • Preclinical Rationale for CAR T Cell Therapy (S. Thomas) • CD19 directed CAR T Cell Therapy in B-NHL (P. Borchmann) • BCMA directed CAR T Cell Therapy in MM (H. Einsele)
10:15	Coffee Break	Coffee Break
10:30	10:30 – 12:00 Workshops • Survivorship (F. van Leeuwen, A. Plate) • Immunotherapy: Chances & Pitfalls (P. Armand, T. Illidge) • Challenges in Older Lymphoma Patients (P. Brice, J. Friedberg) • Minimum Residual Disease (A. Hagenbeek, P. L. Zinzani)	10:30 – 12:00 Biology & Microenvironment (A. van den Berg, C. Steidl) • Microenvironment (R. Küppers) • Genotyping of cHL via Liquid Biopsy (D. Rossi) • Oral Abstract Presentations
12:00	Coffee Break	Coffee Break
12:15	12:15 – 13:45 Biosimilar Rituximab – a New Treatment Option by Sandoz Germany (A. Engert) • Biosimilar Development in Oncology (T. Dingermann) • Clinical evidence for biosimilar rituximab (N. N.) • Treatment of CD20 positive, lymphocyte-predominant Hodgkin lymphoma (D. Eichenauer)	12:15 – 13:45 HL: Tailoring Sequencing and Treatment Targets by Takeda (P. Borchmann) • Considering consolidation after autologous stem cell transplantation (D. Malin) • Relapse after autologous transplant: options and optimising outcomes (A. Sureda) • Considering patient factors: challenging cases and clinical management (All, P. Borchmann)
13:45	Coffee Break	Coffee Break
14:00	14:00 – 15:30 Immunotherapy – Biomechanisms (A. Rosenwald, M. Shipp) • T-cells and PD1 Inhibition in cHL (M. Shipp) • Immune-Evasion (M. K. Gandhi) • Oral Abstract Presentations	14:00 – 15:30 Checkpointblockade in Lymphomas by MSD (A. Engert) • Basics in immunotherapy for lymphomas (D. Wolf) • PD-1 blockade current and future aspects of cHL therapy (P. Borchmann) • PD-1 blockade in NHLs (P. L. Zinzani)
15:30	Coffee Break	Coffee Break
16:00	16:00 – 17:30 Early Stages (R. Hoppe, J. Raemaekers) • Early-Stage Favorable HL: HD16 (A. Engert) • BREACH: Randomized Phase II Trial (M. Andre) • Oral Abstract Presentations	16:00 – 17:30 Immunotherapy – Clinical (P. Armand, M. Hutchings) • Checkmate 205: Cohort D (S. Ansell) • Toxicities from Checkpoint Inhibitor Therapy: Diagnosis, Management and Follow-up (P. J. Bröckelmann) • Oral Abstract Presentations
17:30	Coffee Break	Coffee Break
17:45	17:45 – 19:15 HL: Tailoring Sequencing and Treatment Targets by Takeda (P. Borchmann) • Considering consolidation after autologous stem cell transplantation (D. Malin) • Relapse after autologous transplant: options and optimising outcomes (A. Sureda) • Considering patient factors: challenging cases and clinical management (All, P. Borchmann)	17:30 – 18:15 Relapsed/Refractory HL (C. H. Moskowitz, A. Sureda) • BRaVE: Phase II Trial (A. Hagenbeek) • Novel Agents in First Line Salvage (R. Advani) • Oral Abstract Presentations
19:15	Coffee Break	Coffee Break
19:45	17:45 Opening Ceremony	Closing Remarks
19:45	19:45 Welcome Reception	

Scientific Sessions and Main Program

Workshops

Scientific Symposia

ISHL 11 COLOGNE GERMANY
OCTOBER 27–29, 2018

FINAL PROGRAM

Gürzenich Conference Center • Cologne

GHSQ 
www.ghsq.org

German Hodgkin Study Group
Chairman: Andreas Engert, MD

IMPRINT

Andreas Engert, MD, Symposium and GHSG Chairman
Sven Borchmann, MD, Symposium Secretary
Paul J. Bröckelmann, MD, Symposium Secretary
Dennis A. Eichenauer, MD, Symposium Secretary

German Hodgkin Study Group
Department I for Internal Medicine
University Hospital of Cologne

ISHL11 is hosted by:
Department I for Internal Medicine
University Hospital of Cologne
Director: Prof. Dr. Michael Hallek

Design: Atelier Henri Winter

Printed by: Linsen Druckcenter GmbH

Photos by courtesy of:
Thorsten Kern, P. 5, 12, 13, 23, 24, 27, 31, 33, 34, 36
KölnKongress, P. 14
unsplash.com, P. 15,
Cologne Tourist Board, P. 16, 17

CONFERENCE COMMITTEE

Organizing Committee

Andreas Engert, MD, Symposium and GHSG Chairman
Sven Borchmann, MD, Symposium Secretary
Paul J. Bröckelmann, MD, Symposium Secretary
Dennis A. Eichenauer, MD, Symposium Secretary

German Hodgkin Study Group
Department I for Internal Medicine
University Hospital of Cologne
Kerpener Straße 62, D-50924 Cologne

Phone: +49 (0) 221.478-5933
Fax: +49 (0) 221.478-3778
Email: info@hodgkinsymposium.org
Further Information: www.hodgkinsymposium.org

Conference Management & Industrial Exhibition Secretariat

Gabriele Hanke
Travel & Congress Activities
Marienburger Str. 8; D-40883 Ratingen
Phone: +49 (0) 2102.669 36
Fax: +49 (0) 2102.9648 29
Email: info@tca-hanke.de

INTERNATIONAL SCIENTIFIC COMMITTEE

R. Advani, M. André, S. Ansell, P. Armand, J. Armitage,
O. Baiocchi, M. Björkholm, P. Borchmann, P. Brice,
O. Casasnovas, B. Cheson, J. Connors, V. Diehl, M. Dietlein,
H. T. Eich, M. Federico, J. Friedberg, A. Hagenbeek,
M. L. Hansmann, M. Hertzberg, R. Hoppe, M. Hutchings,
T. Illidge, P. Johnson, R. Küppers, A. Lister, S. Marnitz-Schulze,
C. Mauz-Körholz, C.H. Moskowitz, A. Polliack, J. Radford,
J. Raemaekers, A. Rosenwald, M. Shipp, Y. Song, L. Specht,
C. Steidl, A. Sureda, A. van den Berg, F. van Leeuwen,
J. Walewski, W. Wilson, J. Yahalom, A. Younes, J. Zijlstra,
P. L. Zinzani

SPONSORS

We thank the following pharmaceutical companies for supporting ISHL:



ONCOLOGY

Takeda Oncology | www.takedaoncology.com



Bristol-Myers Squibb

Bristol-Myers Squibb GmbH & Co. KGaA | www.bms.com



A Sandoz Brand

Sandoz Germany
www.hexal.de



MSD

MSD SHARP & DOHME GmbH
www.msd.de



Celgene GmbH
www.celgene.de



Chugai Pharma
www.chugaipharma.de

Merck & Co., Inc.
www.merck.com

AstraZeneca GmbH
www.astrazeneca.de

Mundipharma EDO GmbH
<https://edoncology.com>

Novartis Pharma GmbH
www.novartis.de

Roche Pharma AG
www.roche.de

Sanofi Genzyme GmbH
www.sanofi.de



ACKNOWLEDGEMENTS

We wish to express our appreciation and gratitude to our partners.

ACADEMIC SPONSORS

DFG Deutsche
Forschungsgemeinschaft

Financial support was kindly provided by the Deutsche Forschungsgemeinschaft (DFG) within their program "International Scientific Events".

Karl Musshoff Stiftung

The Karl Musshoff Stiftung kindly supports the Karl Musshoff Prize in the categories "Basic and Translational Science" and "Clinical Research" as well as the "Young Investigator Awards".

B. BRAUN-STIFTUNG

DER GESUNDHEIT NEUE WEGE BEREITEN

Financial support was kindly provided by the B. Braun-Stiftung within their program "Scientific events".

ACADEMIC PARTNERS



Certified with 23 credit points by the European Association for Haematopathology

AEKNO

Accredited by "Ärztchamber Nordrhein"

ONKO
INTERNETPORTAL

In Kooperation mit der
Deutschen Krebsgesellschaft e. V.
www.krebsgesellschaft.de

The ONKO Internetportal is our media partner, in cooperation with Deutsche Krebsgesellschaft e. V.

EXHIBITION HALL

The scientific exhibition takes place at the Gürzenich Conference Center in the "Isabellensaal" on the first floor.

Opening hours of the Exhibition

Saturday, October 27, 2018	12:00–18:00
Sunday, October 28, 2018	08:00–18:00
Monday, October 29, 2018	08:00–18:00

1. Takeda Oncology
2. Bristol-Myers Squibb GmbH & Co. KGaA
3. Sanofi Genzyme GmbH
4. AstraZeneca GmbH
5. Roche Pharma AG
6. Novartis Pharma GmbH
7. MSD SHARP & DOHME GmbH
8. Deutsche Leukämie- & Lymphom-Hilfe e. V.
9. Leukämiehilfe RHEIN-MAIN e. V.




TABLE OF CONTENTS

Conference and Scientific Committee	3
Sponsors Acknowledgements	4–5
Exhibition	6–7
Table of Contents	9
Welcome	11
General Information	12–15
Scientific Program	
Saturday 27.10.2018	18–23
Workshops Scientific Program Scientific Symposia	
Opening Ceremony	
Sunday 28.10.2018	24–28
Scientific Program Poster Session Scientific Symposia	
Monday 29.10.2018	29–33
Scientific Program Poster Session Scientific Symposia	
Closing Remarks	
Oral and Poster Presentations	
WS: Molecular Pathogenesis	35
Immunotherapy – Biomechanisms	36
Biology and Microenvironment	37–40
Early Stages	41–43
Survivorship and Patients' Perspective	44–50
Advanced Stages	51–56
Pediatric Hodgkin Lymphoma	56–59
Immunotherapy – Clinical	59–60
Relapsed/Refractory HL	61–67
Speakers and Chairs	69–71
Award Winners ISHL11	72–73
FSA-Kodex	74
Advertisements	75–76


WELCOME

Dear Colleagues and Friends,

We warmly welcome you to our 11th International Symposium on Hodgkin Lymphoma (ISHL11), hosted by the German Hodgkin Study Group (GHSg). This Symposium has become the central forum for clinicians and scientists involved in Hodgkin Lymphoma research and therapy, enabling in-depth exchange of the latest results and new ideas. Discussing the relevance of new findings for daily clinical practice in Hodgkin Lymphoma is one of the major goals of this Symposium. It will once more be held at the Gürzenich Conference Center in Cologne, which provides a wonderful communicative environment for discussion and networking.

ISHL11 will cover the most recent results in basic research, diagnostics and treatment of Hodgkin Lymphoma and related malignancies. Scientific symposia and workshops will complement the program. This year's core topic will be survivorship. The Karl Musshoff Prize in the categories "Basic and Translational Science" and "Clinical Research" will be presented during the opening ceremony. On top of that, five Young Investigator Awards have been selected by an international committee, based on the evaluation of their abstracts.

We thank all our contributors and cordially welcome you to ISHL11!



Andreas Engert
Symposium Chairman



Sven Borchmann
Symposium Secretary



Paul J. Bröckelmann
Symposium Secretary



Dennis A. Eichenauer
Symposium Secretary



General Information

Conference Secretariat

Gürzenich Cologne | Martinstraße 29–37 | 50667 Cologne

During the conference, you can contact the Secretariat at

Phone: +49 (0) 173 . 93907 30

Email: info@tca-hanke.de

Opening Hours of the Conference Secretariat

Saturday, October 27, 2018 07:00–18:00

Sunday, October 28, 2018 07:00–19:00

Monday, October 29, 2018 07:00–18:00

Accommodation

If you still need a hotel room, please contact the conference management:

Phone: +49 (0) 2102 . 669 36

Email: info@tca-hanke.de

Name Badge

Please make sure to always wear your badge at the conference. If you lose your badge, we will have to charge you a replacement fee.

Catering

During the breaks, complimentary coffee, fruit and refreshments will be available, and other small snacks can be bought. For participants of the scientific symposia, breakfast and lunch will be provided.



Cloakroom

The cloakroom is located in the basement.

Conference Language

The conference language is English.

Continuing Medical Education

The 11th International Symposium on Hodgkin Lymphoma is certified by the European Board for Accreditation in Hematology (formerly EHA) with 23 EBAH credit points.

Please collect your certificates before departure at the registration desk (in the entrance hall of the Gürzenich).

Insurance

The meeting organizers cannot accept liability for personal injuries sustained to Conference participants or for loss or damage of their personal belongings, neither during nor as a result of the meeting.

Internet

There will be free wifi at the Gürzenich Conference Center. Further details and access codes will be provided on site. You can also use the two on-site internet terminals for web browsing and web-based email access.

Prayer Room

A nondenominational prayer room will be available in the conference center. For further details, please contact the Conference Secretariat.



Registration

Pre-registration will close on *October 26, 2018*. All registrations received on or after *October 27* will be considered as on-site registrations and will be charged the on-site fee.

Full registration will include access to the scientific sessions and exhibition, a copy of the program, the welcome reception on *Saturday (October 27)* and all refreshment breaks. You will also receive a name tag; please wear this name tag at all conference events including the scientific symposia.

No refunds will be given.

Speakers Ready Room

The Speakers Ready Room is located next to the registration desk on the ground floor of the Gürzenich Conference Center. Speakers are requested to hand in their PowerPoint presentations in 16:9 format saved on a stick at least 3 hours before their session or the day before if the session starts early in the morning. We can only accept Windows PowerPoint files for upload to the conference system. It is not permitted to use your own laptops or other devices for uploading the files.

Non-Smoking

Please note that there will be a strict non-smoking policy at all conference facilities.



Transportation

The airports closest to Cologne City are Cologne Bonn Airport (CGN; 15km) and Düsseldorf Airport (DUS; 45km).

From Cologne Bonn Airport you can reach Cologne central station by regional rail in about 30 minutes; from Frankfurt Airport to Cologne it takes only an hour by InterCity Express (ICE) and from Düsseldorf Airport about 45 minutes.

Cologne central station is within walking distance (about 10 minutes) from the Gürzenich Conference Center and the Dorint Hotel. You can also take bus no. 132 and get off at "Gürzenichstraße". The other hotels recommended by the Conference Organization can easily be reached by public transport. Cologne has an efficient public transport system, but the recommended hotels, the venue as well as other places of interest are within a comfortable walking distance from each other. For those who are traveling by car, we recommend to use the parking ground "Heumarkt" (about 3 minutes walking distance from the Gürzenich).

If you want to take a taxi, you can either get in directly at one of the numerous taxi stands or you can order a taxi by phone from one of the taxi call centres.

Welcome Reception

On Saturday evening, the conference will be opened officially. After the Opening Ceremony, all participants are warmly invited to join us at our Get Together event at the Gürzenich Conference Center. This event is a great opportunity to meet and chat with many colleagues involved in Hodgkin Lymphoma research and treatment. Drinks and snacks will be provided.



The Gürzenich and Cologne

The *Gürzenich Conference Center* is situated right in the heart of Cologne, an ideal location to explore all the different facets of one of the liveliest cities in Germany.

The Conference Site: Completed in 1447, the Gürzenich was the largest secular building of the city built in the middle ages. It has a Gothic façade and a spectacular roof lined with turrets. It was used to receive many guests that were deemed very important, including kings and queens.

The Old Town: Located between the lovely Rhine embankment promenade and the world famous Cologne Cathedral, the old town offers a lovely backdrop for a walk. If you are ready for a bit of exercise, you might like to climb the cathedral tower to get a stunning bird's eye view of the town. The Farina House just across the Gürzenich is the birthplace of the famous Eau de Cologne. It shows a major part of Cologne's economic and social history by way of the perfume industry. If you walk a bit further along the Rhine towards the South end of the city, you will see a shiny glass building right on the banks of the river. It houses the unique Chocolate Museum – a very nice place for a relaxing break.



Culture: Kolumba, the art museum of the archbishop of Cologne, is both an architectural and a cultural highlight. It is a fascinating new building designed by Peter Zumthor and houses an impressive collection of art from ancient times to the present day. Another place worth a visit is the Museum Ludwig, where you can find one of the most distinguished collections of 20th century art, ranging from Russian avant-garde to works of famous contemporary artists.

Beer Culture: The place to dive into Cologne's beer culture is Brauhaus Früh. If you prefer a cosier place, you could try Altstadt Päßgen. Both offer traditional, local meals that will keep you going for a long time.

Shopping: The main shopping streets are Schildergasse and Hohe Straße. If you are looking for smaller, more exclusive boutique shops, we recommend to visit the Mittelstraße. In Germany, shops usually do not open on Sundays, however, the shopping arcade at the train station is open 7 days a week.

Saturday, 27.10.2018

WORKSHOPS

Workshop 1 (parallel sessions) 08:45–10:15**Radiotherapy in Salvage** ROOM: MARTIN / AUGUSTIN

Simone Marnitz-Schulze (Cologne, DE), Joachim Yahalom (New York, US)

08:45–09:00 Radiotherapy for salvage – Principles and IIROG guidelines	Louis Constine (Rochester, US)
09:00–09:15 Radiotherapy techniques for salvage and re-irradiation	Bouthaina Dabaja (Houston, US)
09:15–09:30 Long-term considerations in salvage therapy	Lena Specht (Copenhagen, DK)
09:30–09:45 Radiation- and immunotherapy for relapsed or refractory HL	Christian Baues (Cologne, DE)
09:45–10:00 Future of RT in Salvage – new approaches, alternatives to high dose chemotherapy	Joachim Yahalom (New York, US)
10:00–10:15 Panel discussion	Led by Simone Marnitz-Schulze and Joachim Yahalom

Workshop 2 (parallel sessions) 08:45–10:15**Molecular Pathogenesis** ROOM: KLEINER SAAL

Martin-Leo Hansmann (Frankfurt a. M., DE), Christian Steidl (Vancouver, CA)

08:45–09:05 Somatic gene mutations in NLPPL and THRLBCL	Sylvia Hartmann and Bianca Schuhmacher (Frankfurt a. M., DE)
09:05–09:25 Microenvironment biology and outcome prediction in pediatric Hodgkin Lymphoma	Anja Mottok (Ulm, DE)
♀ T001 Abstract Talk CK2A is overexpressed, active and targetable with silmitasertib In classical Hodgkin Lymphoma	Andrea Visentin (Padova, IT)
♀ T002 Abstract Talk Low B-cell content at diagnosis is associated with adverse outcome in advanced stage classical Hodgkin Lymphoma	Wolfram Klapper (Kiel, DE)
♀ T003 Abstract Talk ROR-1 receptor is a potential therapeutic target in classical Hodgkin Lymphoma	George Rassidakis (Stockholm, SE)

Workshop 3 (parallel sessions) 08:45–10:15**Developing Health Care Environments** ROOM: MARSILIUSSAAL

Anton Hagenbeek (Amsterdam, NL), Oliver Henke (Moshi, TZ)

08:45–09:05 Challenges at a developing cancer center in East Africa	Oliver Henke (Moshi, TZ)
09:05–09:25 Takeda Access to Medicine Program in Sub-Saharan Africa	Judith Kinley (Cambridge, US)
09:25–09:45 Hodgkin Lymphoma care in current Venezuela	Maria Alejandra Torres Viera (Caracas, VE)
09:45–10:15 Panel discussion	Led by Anton Hagenbeek and Oliver Henke

Workshop 4 (parallel sessions) 08:45–10:15**Positron Emission Tomography** ROOM: GROSSER SAAL

Markus Dietlein (Cologne, DE), Michel Meignan (Créteil, FR)

08:45–09:15 PET/CT – The perspective from the German Hodgkin Study Group	Carsten Kobe (Cologne, DE)
09:15–09:45 PET guided strategy in Hodgkin lymphoma: issues and perspectives	Andrea Gallamini (Nice, FR)
09:45–10:15 Measurement of metabolic volume and threshold in Hodgkin Lymphoma: how to move to a standard	Olivier Casasnovas (Dijon, FR)

Workshop 5 (parallel sessions) 10:30–12:00**Survivorship** ROOM: KLEINER SAAL

Flora van Leeuwen (Amsterdam, NL), Ananda Plate (Munich, DE)

10:30–10:45 Genetic determinants of radiation-induced breast cancer after HL	Flora van Leeuwen (Amsterdam, NL)
10:45–11:00 Genetic polymorphisms associated with anthracycline-induced cardiotoxicity	Leszek Wojnowski (Mainz, DE)
11:00–11:15 Genetic determinants for acute radiation toxicity	Catharine West (Manchester, UK)
11:15–11:30 Genetic susceptibility for treatment-related adverse effects: How can we make significant progress?	Lindsay Morton (Bethesda, US)
11:30–12:00 Panel discussion	



Workshop 6 (parallel sessions) 10:30–12:00

Immunotherapy: Chances & Pitfalls ROOM: GROSSER SAAL

Philippe Armand (Boston, US), Tim Illidge (Manchester, UK)

10:30–11:00 Tim Illidge (Manchester, UK)

The role of radiotherapy for Hodgkin Lymphoma in the era of PD-1 blockade

11:00–11:30 Philippe Armand (Boston, US)

Impact of PD-1 blockade on the treatment landscape of Hodgkin Lymphoma

11:30–12:00 Steve Ansell (Rochester, US)

Pitfalls in clinical trial design and interpretation with immunotherapy

Workshop 7 (parallel sessions) 10:30–12:00

Challenges in Older Lymphoma Patients ROOM: MARSILIUSSAAL

Pauline Brice (Paris, FR), Jonathan Friedberg (Rochester, US)

10:30–10:45 Alessandra Tucci (Brescia, IT)

The role of geriatric assessments in lymphoma

10:45–11:00 Pauline Brice (Paris, FR)

Chemotherapy combinations in elderly HL

11:00–11:15 Boris Böll (Cologne, DE)

German experience in elderly HL

11:15–11:30 Jonathan Friedberg (Rochester, US)

Brentuximab combinations in elderly HL, including checkpoint inhibitor

11:30–11:45 Andrew Evens (New Jersey, US)

Brentuximab / chemotherapy combinations in elderly HL

11:45–12:00 Led by Pauline Brice and Jonathan Friedberg

Panel discussion

Workshop 8 (parallel sessions) 10:30–12:00

Minimum Residual Disease DORINT HOTEL: MARTIN / AUGUSTIN

Anton Hagenbeek (Amsterdam, NL), Pier Luigi Zinzani (Bologna, IT)

10:30–10:50 Marie Helene Delfau-Larue (Paris, FR)

Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in FL

10:50–11:10 Mark Roschewski (Bethesda, US)

The role of ctDNA in research and decision making—Lessons from ctDNA in DLBCL

11:10–11:30 Sven Borchmann (Cologne, DE)

The Hodgkin Lymphoma MRD consortium

Michiel Pegtel (Amsterdam, NL)

11:30–12:00 Led by Pier-Luigi Zinzani and Anton Hagenbeek

Panel discussion

Scientific Symposium (Sandoz Germany) 12:15–13:45

Biosimilar Rituximab – a New Treatment Option

Andreas Engert (Cologne, DE) ROOM: GROSSER SAAL

12:15–12:45 Theodor Dingermann (Frankfurt a.M., DE)

Biosimilar Development in Oncology

12:45–13:15 N. N.

Clinical evidence for biosimilar rituximab

13:15–13:45 Dennis A. Eichenauer (Cologne, DE)

Treatment of CD20 positive, lymphocyte-predominant Hodgkin Lymphoma

Scientific Session 1

14:00–15:30

Immunotherapy – Biomechanisms ROOM: GROSSER SAAL

Andreas Rosenwald (Würzburg, DE), Margaret Shipp (Boston, US)

14:00–14:20 Margaret Shipp (Boston, US)
T-cells and PD1 Inhibition in cHL

14:20–14:40 Maher K. Gandhi (Brisbane, AU)
Immune Evasion

Q **14:40–14:50 | T004**
Expression of PD-1 and PD-L1 increase in multiple consecutive biopsies in patients with classical Hodgkin Lymphoma, *Ingrid Glimelius (Uppsala, SE)*

Q **14:50–15:00 | T005**
Trabectedin inhibits classical Hodgkin Lymphoma growth, monocytes immunosuppressive polarization by tumor cells and synergizes with the CCR5-antagonist Maraviroc, *Naïke Casagrande (Aviano, IT)*

🕒 **Poster Pitch | P002**
Development of an α -CD30 bispecific antibody immunotherapy for Hodgkin Lymphoma, *Cindy L. Schwartz (Milwaukee, US)*

Q **15:05–15:15 | T006**
The peripheral blood neutrophil PD-L1 and lymphocyte PD-1 axis in classical Hodgkin Lymphoma at diagnosis, *Annarosa Cuccaro (Rome, IT)*

Q **15:15–15:25 | T007**
PD-L1+ and IDO-1+ tumor-associated macrophages predict survival in primary classical Hodgkin Lymphoma, *Kristiina Karihtala (Helsinki, FI)*

Scientific Symposium 16:00–17:30 (Developed by Medscape Education, supported by Takeda)

Advanced Hodgkin Lymphoma: How Can We Do Better?

Mark Hertzberg (Sydney, AU) ROOM: GROSSER SAAL

16:00–16:10 Mark Hertzberg (Sydney, AU)
Introduction

16:10–16:30 Astrid Pavlovsky (Buenos Aires, AR)
Can we do better in front-line?

16:30
Audience Q&A with panel discussion

16:35–16:55 Craig H. Moskowitz (Miami, US)
Can we do better with salvage?

16:55
Audience Q&A with panel discussion

17:00–17:20 Martin Hutchings (Copenhagen, DK)
Assessing risk of failure throughout treatment

17:20
Audience Q&A with panel discussion

17:25 Mark Hertzberg (Sydney, AU)
Conclusion



OPENING CEREMONY

Gürzenich Conference Center ROOM: GROSSER SAAL **17:45**

Introduction and Welcome from the Symposium Chairman Andreas Engert (Cologne, DE)

Welcoming Address Volker Diehl (Cologne, DE)

Welcoming Address Stefan Herzig (Cologne, DE)

Keynote Lecture Jan Geissler (Munich, DE)
“The role of patient advocacy and patient involvement in research”

Award Ceremony
Karl Musshoff Prizes 2018
Young Investigator Awards 2018

WELCOME RECEPTION

Gürzenich Conference Center **19:45**

GÜRZENICH BASEMENT

Sunday, 28.10.2018



Scientific Session 2

07:30–09:00

Interactive Case Discussions ROOM: GROSSER SAAL

Faculty: Mark Hertzberg (Sydney, AU), Andrew Lister (London, UK)
Presenters: Dennis A. Eichenauer (Cologne, DE), Joanna Romejko-Jarosinska (Warsaw, PL), Otavio Baiocchi (São Paulo, BR), Sven Borchmann (Cologne, DE)

Presentation of difficult and controversial Hodgkin Lymphoma cases with a focus on interaction and discussion

1. Stage IV NPLHL (*D. A. Eichenauer*)
2. Elderly cHL (*J. Romejko-Jarosinska*)
3. HIV-positive HL (*O. Baiocchi*)
4. Progress on anti-PD1 moAb (*S. Borchmann*)

Scientific Symposium (Chugai)

09:15–10:15

Oncology Meets Autoimmunity ROOM: GROSSER SAAL

Andreas Engert (Cologne, DE)

09:15 – 09:45 Jörg Henes (Tübingen, DE)
Autotransplant in systemic sclerosis

09:45 – 10:15 Daniel Wolff (Regensburg, DE)
Autoimmunity in chronic GVHD

Scientific Session 3

10:30–12:00

Biology & Microenvironment ROOM: GROSSER SAAL

Anke van den Berg (Groningen, NL), Christian Steidl (Vancouver, CA)

10:30–10:50 Ralf Küppers (Essen, DE)
Microenvironment

10:50–11:10 Davide Rossi (Bellinzona, CH)
Genotyping of cHL via Liquid Biopsy

Q **11:10–11:20 | T008**
Genotyping circulating tumor DNA of pediatric Hodgkin Lymphoma patients to determine pathogenic mechanisms and monitor therapy, *Andreas Bräuninger (Gießen, DE)*

Q **11:20–11:30 | T009**
Circulating tumor DNA as a biomarker for the noninvasive genotyping and monitoring of classical Hodgkin Lymphoma, *Ranjana Advani (Stanford, US)*

Q **Poster Pitch | P019**
Functional analysis of CD30 in Hodgkin and anaplastic large cell lymphoma cell lines by CRISPR/Cas9-mediated gene knockout, *Annika Weib (Essen, DE)*

Q **Poster Pitch | P021**
Copy number aberrations in cell-free DNA of Hodgkin Lymphoma *Lieslot Buedts (Leuven, BE)*

Q **11:40–11:50 | T010**
Clinical validation of an extracellular vesicle associated miRNA detection assay to monitor therapy response in classical Hodgkin Lymphoma patients, *Esther Drees (Amsterdam, NL)*

Q **11:50–12:00 | T011**
Molecular mechanisms in the pathogenesis of composite lymphomas *Anna Lollies (Essen, DE)*

Scientific Symposium (Takeda)

12:15–13:45

Tailoring Sequencing and Treatment Targets

Peter Borchmann (Cologne, DE) ROOM: GROSSER SAAL

12:15–12:20 Peter Borchmann (Cologne, DE)
Welcome and introduction

12:20–12:35 Daniel Molin (Uppsala, SE)
Considering consolidation after autologous stem cell transplantation

12:35–12:50 Anna Sureda (Barcelona, ES)
Relapse after autologous transplant: options and optimising outcomes

12:50–13:40 All, facilitated by Peter Borchmann (Cologne, DE)
Considering patient factors: challenging cases and clinical management

13:40–13:45 Peter Borchmann (Cologne, DE)
Summary and close

Scientific Session 4

14:00–15:30

Early Stages **ROOM: GROSSER SAAL**

Richard Hoppe (Stanford, US), John Raemaekers (Nijmegen, NL)


14:00–14:20

Early-Stage Favorable HL: HD16

Andreas Engert
(Cologne, DE)**14:20–14:40**

BREACH: Randomized phase II trial

Marc André (Yvoir, BE)

Q **14:40–14:50 | T012**Relapses in early PET-negative stage I/II Hodgkin Lymphoma (HL) after combined modality treatment or chemotherapy only in the EORTC/LYSA/FIL H10 trial, *Valeria Fiaccadori (London, UK)*Q **14:50–15:00 | T013**Maximum tumour dimension at baseline is associated with event-free survival in PET negative patients with stage IA/IIA Hodgkin Lymphoma in the UK NCRI RAPID trial, *Tim Illidge (Manchester, UK)*🕒 **Poster Pitch | P027**Cardiovascular radiation dosimetry and predicted cardiovascular risks from involved field radiotherapy within the UK 'RAPID' trial in early low-risk Hodgkin Lymphoma, *David Cutter (Oxford, UK)*🕒 **Poster Pitch | P029**Quality assurance of involved-node radiotherapy: first results of the HD17-trial of the GHSG, *Jan Kriz (Münster, DE)*Q **15:10–15:20 | T014**Multicentric Italian experience in treatment of nodular lymphocyte predominant Hodgkin Lymphoma (NLPHL) in the Rituximab era, *Manuel Gotti (Pavia, IT)*Q **15:20–15:30 | T015**Brentuximab Vedotin and AVD chemotherapy followed by reduced dose/volume radiotherapy in patients with early stage, unfavorable Hodgkin Lymphoma, *Joanna Yang (New York, US)*

Poster Session

GÜRZENICH, KLEINER SAAL

15:30–16:00

Please join the poster presentation and take the chance to discuss the results with your colleagues.

Scientific Symposium
(Bristol-Myers Squibb)

16:00–17:30

Focus on cHL: Current Insights and Future Perspectives

Peter Borchmann (Cologne, DE) **ROOM: GROSSER SAAL****16:00–16:05**

Welcome and Introduction

Peter Borchmann
(Cologne, DE)**16:05–16:25**

The Evolving cHL Treatment Landscape

Graham Collins (Oxford, UK)

16:25–16:45

Understanding the Unmet Needs in cHL

Peter Borchmann
(Cologne, DE)**16:45–17:05**

Focus on Biomarkers: Biology as a Key Driver of Therapeutic Benefit

Margaret Shipp (Boston, US)

17:05–17:25

Panel Discussion

All

17:25–17:30

Concluding Remarks

Peter Borchmann
(Cologne, DE)

Survivorship & Patients' Perspective ROOM: GROSSER SAAL

Flora van Leeuwen (Amsterdam, NL), Ananda Plate (Munich, DE)

17:45–18:05 Lorna Warwick (Toronto, CA)
 What Patients Really Want:
 The Global Lymphoma Patient Survey

18:05–18:25 Hans Knoop (Amsterdam, NL)
 Cognitive Behavioral Therapy for Fatigue in HL

18:25–18:45 Lindsay Morton (Bethesda, US)
 Genetic Susceptibility

Q **18:45–18:55 | T016**
 Employment situation among long-term Hodgkin Lymphoma survivors in Europe: an analysis of patients from nine consecutive EORTC-LYSA trials, *Maja Maraldo (Copenhagen, DK)*

🕒 **Poster Pitch | P036**
 Early-stage Hodgkin Lymphoma (HL) in the modern era: harnessing simulation modeling to delineate long-term patient outcomes, *Andrew Evens (Boston, US)*

🕒 **Poster Pitch | P060**
 The reciprocal relation between cancer-related fatigue and physical and psychosocial functioning in survivors of Hodgkin Lymphoma, *Nele Stadtbäumer (Aachen, DE)*

Q **18:55–19:05 | T017**
 Is routine laboratory testing useful in detecting relapse in patients with classic Hodgkin Lymphoma in first remission?, *Ryan Lynch (Seattle, US)*

Q **19:05–19:15 | T018**
 Contemporarily treated Hodgkin Lymphoma patients have childbearing potential in line with matched comparators, *Ingrid Glimelius (Stockholm, SE)*

Advanced Stages ROOM: GROSSER SAAL

Volker Diehl (Cologne, DE), Peter Johnson (Southampton, UK)

07:30–07:50 John Radford (Manchester, UK)
 ECHELON1 Update

07:50–08:10 Peter Borchmann (Cologne, DE)
 HD18 Update

08:10–08:30 Olivier Casasnovas (Dijon, FR)
 LYSA AHL2011 Phase III Study

Q **08:30–08:40 | T019**
 Potential impact of consolidation radiation therapy for advanced Hodgkin Lymphoma: a secondary modeling analysis of SWOG S0816, *Chul S. Ha (San Antonio, US)*

Q **08:40–08:50 | T020**
 Baseline PET features as predictors of outcome in advanced HL: a prospective evaluation of UK patients in the RATHL trial (CRUK/07/033), *Sally Barrington (London, UK)*

Q **08:50–09:00 | T021**
 B-CAP (brentuximab vedotin, cyclophosphamide, doxorubicin and prednisolone) in older patients with advanced-stage Hodgkin Lymphoma: results of a phase II intergroup trial by the German Hodgkin Study Group (GHSG) and the Nordic Lymphoma Group (NLG), *Alexander Fosså (Oslo, NO)*

Scientific Symposium (Celgene)**CAR T Cell Therapies: Hype or Hope?** ROOM: GROSSER SAAL

Hermann Einsele (Würzburg, DE)

Preclinical Rationale for CAR T Cell Therapy Simone Thomas (Regensburg, DE)

CD19 directed CAR T Cell Therapy in B-NHL Peter Borchmann, (Cologne, DE)

BCMA directed CAR T Cell Therapy in MM Hermann Einsele (Würzburg, DE)

Scientific Session 7

10:30–12:00

Pediatric HL ROOM: GROSSER SAAL

Christine Mauz-Körholz (Gießen, DE), Kara M. Kelly (New York, US)

10:30–10:50
PD1/-L1 Expression in Pediatric HL
Stefan Gattenlöhner (Gießen, DE)

10:50–11:10
Genotyping in Familial HL
Jun Yang (Memphis, US)

11:10–11:30
Functional and Financial Outcomes after Treatment for Pediatric Hodgkin Lymphoma
Susan Parsons (Boston, US)

Q 11:30–11:40 | T022

Survival by race/ethnicity in pediatric and adolescent patients with Hodgkin Lymphoma: a pooled analysis of contemporary Children's Oncology Group trials, *Justine Kahn (New York, US)*

Q 11:40–11:50 | T023

Safety and early response to the first 2 cycles of Brentuximab Vedotin substituting vincristine in the OEPA/COPDAC regimen for high risk pediatric Hodgkin Lymphoma (HL), *Monika Metzger (Memphis, US)*

Q 11:50–12:00 | T024

The feasibility of deep inspiration breath-hold in children: results of the TEDDI pilot study, *Maja Maraldo (Copenhagen, DK)*

Scientific Symposium (MSD)

12:15–13:45

Checkpointblockade in Lymphomas

Andreas Engert (Cologne, DE) ROOM: GROSSER SAAL

12:15–12:35
Basics in immunotherapy for lymphomas
Dominik Wolf (Innsbruck, AT)

12:35–12:55
PD-1 blockade current and future aspects of cHL therapy
Peter Borchmann (Cologne, DE)

12:55–13:15
PD-1 blockade in NHLs
Pier Luigi Zinzani (Bologna, IT)

Scientific Session 8

14:00–15:30

Immunotherapy – Clinical ROOM: GROSSER SAAL

Phillippe Armand (Boston, US), Martin Hutchings (Copenhagen, DK)

14:00–14:20
Checkmate 205: Cohort D
Steve Ansell (Rochester, US)

14:20–14:40
Toxicities from Checkpoint Inhibitor Therapy: Diagnosis, Management and Follow-up
Paul J. Bröckelmann (Cologne, DE)

Q 14:40–14:50 | T025

Brentuximab Vedotin in combination with Nivolumab in patients with relapsed or refractory Hodgkin Lymphoma: follow-up results from the phase 1/2 study, *Alex Herrera (Duarte, US)*

Q 14:50–15:00 | T026

A phase II study of SHR-1210, an anti-PD-1 antibody, in Chinese patients with relapsed/refractory classic Hodgkin Lymphoma, *Yuqin Song (Beijing, CN)*

Poster Pitch | P105

A phase II study of Pembrolizumab (PEM) followed by AVD for frontline treatment of classical Hodgkin Lymphoma (cHL): interim results, *Pamela Allen (Decatur, US)*

Q 15:05–15:15 | T027

Phase 2 study of frontline Brentuximab Vedotin plus Nivolumab in patients with Hodgkin Lymphoma aged ≥ 60 years, *Jonathan W. Friedberg (Rochester, US)*

Q 15:15–15:25 | T028

Allogeneic stem cell transplantation (allo-SCT) for relapsed/refractory classical Hodgkin Lymphoma (cHL) patients treated with Nivolumab is associated with an unprecedented low relapse rate, *Luca Castagna (Rozzano, IT)*

**Poster Session** GÜRZENICH, KLEINER SAAL

15:30–16:00

Please join the poster presentation and take the chance to discuss the results with your colleagues.

Relapsed/Refractory HL ROOM: GROSSER SAAL

Craig H. Moskowitz (Miami, US), Anna Sureda (Barcelona, ES)

16:00–16:20 Anton Hagenbeek
BRaVE: Phase II Trial (Amsterdam, NL)

16:20–16:40 Ranjana Advani
Novel Agents in First Line Salvage (Stanford, US)

♀ **16:40–16:50 | T029**
Second autologous stem cell transplantation (ASCT) for relapsed or refractory (r/r) Hodgkin Lymphoma (HL) after a previous autograft: a registry study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation, *Carmen Martinez (Barcelona, ES)*

♀ **16:50–17:00 | T030**
Bendamustine, gemcitabine, and dexamethasone (BGD) chemotherapy followed by autologous stem cell transplantation (ASCT) is effective treatment for patients with relapsed/refractory Hodgkin Lymphoma (rHL) – Results of the Polish Lymphoma Research Group (PLRG) pilot study – Pre-PLRG-HL1 (BURGUND), *Ewa Paszkiewicz-Kozik (Warsaw, PL)*

♂ **Poster Pitch | P118**
Long term safety and efficacy of combination of Brentuximab Vedotin and Ipilimumab or Nivolumab in relapsed/refractory Hodgkin Lymphoma: a trial of the ECOG-ACRIN Cancer Research Group (E4412), *Catherine Diefenbach (New York, US)*

♂ **Poster Pitch | P126**
PD-1 blockade for Hodgkin Lymphoma after allogeneic stem cell transplantation, *Anna Sureda (Barcelona, ES)*

♀ **17:10–17:20 | T031**
Five-year progression-free survival outcomes from a pivotal phase 3 study of consolidative Brentuximab Vedotin after autologous stem cell transplant in patients with Hodgkin Lymphoma at risk of relapse or progression (AETHERA), *Craig H. Moskowitz (Miami, US)*

♀ **17:20–17:30 | T032**
Relapse after early-stage favorable Hodgkin Lymphoma: disease characteristics, treatment strategies and their outcome, *Paul J. Bröckelmann (Cologne, DE)*

**Closing Remarks** ROOM: GROSSER SAAL

17:45

Andreas Engert (Cologne, DE)

ABSTRACTS

ORAL AND POSTER PRESENTATIONS

Posters will be displayed in the “Kleiner Saal” on Sunday (October 28) and Monday (October 29).

Poster presenters are kindly asked to be present at their poster boards during the Poster Sessions on Sunday (October 28) and Monday (October 29), 15:30 to 16:00 to discuss their research.

WS: Molecular Pathogenesis (Biology and Microenvironment)

Talk

Q T001 (0006)

CK2A is overexpressed, active and targetable with silmitasertib in classical Hodgkin Lymphoma

Visentin A, Frezzato F, Severin F, Pizzi M, Martini V, Raggi F, Imbergamo S, Scomazzon E, Pravato S, Manni S, Facco M, Carlo-Stella C, Semenzato G, Piazza F, Trentin L

Q T002 (0076)

Low B-cell content at diagnosis is associated with adverse outcome in advanced stage classical Hodgkin Lymphoma

Jachimowicz RD, Pieper L, Gontarewicz A, Plütschow A, Haverkamp H, Reinke S, Thorns C, Hansmann ML, Möller P, Rosenwald A, Stein H, Kohler C, Glehr G, Reinhardt HC, Borchmann P, v. Tresckow B, Altenbuchinger M, Spang R, Engert A, Klapper W

Q T003 (0171)

ROR-1 receptor is a potential therapeutic target in classical Hodgkin Lymphoma

Velentza L, Zerdas I, Manesh AHD, Tsesmetzis N, Hojat-Farsangi M, Ghaderi A, Drakos E, Palma M, Österborg A, Mellstedt H, Rassidakis GZ

Session 1: Immunotherapy – Biomechanisms

Talk

Q T004 (0051)

Expression of PD-1 and PD-L1 increase in multiple consecutive biopsies in patients with classical Hodgkin Lymphoma
Glimelius I, Amini RM, Ginman B, Molin D, Enblad G, Hollander P

Q T005 (0077)

Trabectedin inhibits classical Hodgkin Lymphoma growth, monocytes immunosuppressive polarization by tumor cells and synergizes with the CCR5-antagonist Maraviroc
Casagrande N, Borghese C, Mariotto E, Vicenzetto C, Favero A, Aldinucci D

*CB and NC co-first authors

Q T006 (0079)

The peripheral blood neutrophil PD-L1 and lymphocyte PD-1 axis in classical Hodgkin Lymphoma at diagnosis
Cuccaro A, Zangrilli I, Corrente F, Cupelli E, Fatone F, Galli E, Maiolo E, Annunziata S, Rufini V, Balducci M, D'Alò F, Bellesi S, De Stefano V, Hohaus S

Q T007 (0099)

PD-L1+ and IDO-1+ tumor-associated macrophages predict survival in primary classical Hodgkin Lymphoma
Karihtala K, LeivonenSK, Pellinen T, Brück O, Karjalainen-Lindsberg ML, Mustjoki S, Leppä S

Poster Pitch

🌀 P002 (0061)

Development of an α -CD30 bispecific antibody immunotherapy for Hodgkin Lymphoma
Schwartz CL, Oldham RAA, Faber ML, Thakur A, Lum LG, Medin JA

Posters

P001 (0015)

Hodgkin's variant of Richter transformation in the Czech Republic
Mociková H, Sýkorová A, Marková J, Klásková K, Šimkovič M, Smolej L, Kalinová M, Campr V, Kozák T, on behalf of the Czech Hodgkin Lymphoma Study Group

P003 (0157)

Microsatellite and chromosomal instability constitute two mechanisms that independently lead to genomic instability in Hodgkin Lymphoma
M'Kacher R, Cuceu C, Colicchio B, Junker S, Plassa F, Mika J, Frenzel M, Al Jawhari M, Hempel WM, O'Brien G, Morat L, Girinsky T, Dieterlen A, Polanska J, Badie C, Jeandier E, Carde P

Session 3: Biology and Microenvironment

Talk

Q T008 (0050)

Genotyping circulating tumor DNA of pediatric Hodgkin Lymphoma patients to determine pathogenic mechanisms and monitor therapy
Bräuninger A, Desch AK, Kunze K, Boten A, Brobeil A, Rummel M, Kurch L, Georgi T, Kluge R, Mauz-Körholz C, Körholz D, Gattenlöhner S

Q T009 (0083)

Circulating tumor DNA as a biomarker for the noninvasive genotyping and monitoring of classical Hodgkin Lymphoma
Jin MC, Kurtz DM, Esfahani MS, Sworder BJ, Schroer-Martin J, Soo J, Glover C, Roschewski M, Wilson W, Düehrsen U, Hüttmann A, Rossi D, Gaidano G, Westin J, Diehn M, Advani R, Alizadeh AA

Q T010 (0113)

Clinical validation of an extracellular vesicle associated miRNA detection assay to monitor therapy response in classical Hodgkin Lymphoma patients

Drees EEE, van Eijndhoven MAJ, Ciocanea-Teodorescu I, Groenewegen NJ, Prins LI, Tran X, Valles A, Koppers-Lalic D, Aparicio E, Hackenberg M, de Jong D, Zijlstra JM, Pegtel DM

Q T011 (0162)

Molecular mechanisms in the pathogenesis of composite lymphomas

Lollies A, Schneider M, Hartmann S, Mathas S, Tiacci E, Weniger MA, Johansson P, Dürig J, Klein-Hitpass L, Hansmann ML, Küppers R

Poster Pitch**🕒 P019 (0158)**

Functional analysis of CD30 in Hodgkin and anaplastic large cell lymphoma cell lines by CRISPR/Cas9-mediated gene knockout

Weiß AL, Lollies A, Kretzmer F, Weniger MA, Küppers R

🕒 P021 (0168)

Copy number aberrations in cell-free DNA of Hodgkin Lymphoma

Buedts L, Tousseyn T, Gheysens O, Finalet-Ferreiro J, Dehaspe L, Verhoef G, Smits S, Vermeesch J, Vandenbergh P

Posters**P004 (0011)**

Array-based DNA methylome analyses of classical Hodgkin Lymphoma

Vogt J, Kretzmer H, Ammerpohl O, Vallés Uriate L, Drexler HG, Wagener R, López C, Siebert R

P005 (0036)

The role of TCF3 in classical Hodgkin Lymphoma

Veenstra R, Kluiver J, Visser L, Diepstra A, van den Berg A

P006 (0037)

Recurrent exportin 1 mutations in patients with classical Hodgkin Lymphoma

Navarro-Bailón A, Jiménez C, Alonso-Álvarez S, Antón A, Chillón MC, Alcoceba M, García-Álvarez M, Prieto I, Medina A, González-de-la-Calle V, González M, Sarasquete ME, García-Sanz R

P007 (0043)

TARC immunohistochemistry in the diagnosis of classical Hodgkin Lymphoma

Veldman C, Rosati S, van den Berg A, Visser L, Plattel W, Diepstra A

P008 (0053)

Whole-slide-image analysis of the tumormicroenvironment in classical Hodgkin Lymphoma

Pieper L, Reinke S, Jachimowicz R, Plütschow A, Engert A, Klapper W

P009 (0069)

CD2 is an important adhesion molecule in the initial interaction between Hodgkin Reed-Sternberg cells and rosetting T cells

Veldman J, van den Berg A, Visser L, Diepstra A

P010 (0073)

A new reliable and highly specific antibody to detect SOCS1 (silencer of cytokine signaling 1)

Weissinger SE, Zahn M, Mellert K, Marienfeld R, Moldenhauer G, Möller P

P012 (0081)

Soluble cytokines in Hodgkin Lymphoma patients treated with a GHSg policy: an analysis of the Czech Hodgkin Lymphoma Study Group

Prochazka V, Lukasova M, Kriegova E, Sykrova A, Mocikova H, Papajik T, Belada D, Markova J, Klaskova K, Hanackova V, Gabcova G, Mikulková Z, Stepankova P, on behalf of the Czech Hodgkin Lymphoma Study Group

P013 (0088)

Digital image analysis of the microenvironment in classical Hodgkin Lymphoma comparing primary tumor and relapse
Jochims F, Kretschmer S, Jachimowicz R, Fend F, Ott G, Hansmann ML, Thorns C, Plütschow A, Engert A, Klapper W

P014 (0098)

CD47 is expressed on Hodgkin Reed Sternberg cells in classical Hodgkin Lymphoma
Alonso A, Lopez-Pereira B, Corte MD, Alonso-Alvarez S, Fernandez-Vega I, García-Moro MA, Bernal T, Alonso-Arias R and Colado E

P015 (0100)

Characterization of T-cell phenotypes with clinical significance in patients with classical Hodgkin Lymphoma
Karihtala K, Leivonen SK, Pellinen T, Brück O, Karjalainen-Lindsberg ML, Mustjoki S, Leppä S

P016 (0104)

Phenotypic characterization of circulating T and NK cells in Hodgkin Lymphoma patients in relation to tumor burden and treatment
Mulder TA, Heimersson K, Näsman-Glaser B, Hansson L and Palma M

P017 (0120)

Immunologic biomarkers of response and resistance to brentuximab vedotin in patients with relapsed or refractory classical Hodgkin Lymphoma
Song JY, Chan WC, Warden C, Wu X, Weisenburger DD, Chen R, Herrera AF

P018 (0139) withdrawn

GATA3 expression distinguishes classic Hodgkin Lymphoma from nodular lymphocyte Hodgkin Lymphoma
Epari S, Vidya R, Jain H, Bagal B, Laskar S, Sengar M, Gujral S, Shet T

P020 (0164)

Extracellular circulating DNA in Hodgkin Lymphoma patients: biological correlates and prognostic impact
Dujmović D, Bašić Kinda S, Radman I, Lauc G, Ilić I, Aurer I

P022 (0170)

The tumor suppressor SAMHD1 is downregulated by MYC in classical Hodgkin Lymphoma
Xagoraris I, Vassilakopoulos T, Herold N, Tsesmetzis N, Houry J, Drakos E, Rassidakis G

Session 4: Early Stages**Talk****Q T012 (0066)**

Relapses in early PET-negative stage I/II Hodgkin Lymphoma (HL) after combined modality treatment or chemotherapy only in the EORTC/LYSA/FIL H10 trial
Fiaccadori V, Neven A, Gac AC, Rigacci L, Girinsky T, Meignan M, Hutchings M, Versari A, Reman O, Ricardi U, Andre M, Federico M, Raemaekers J, Fortpied C

Q T013 (0095)

Maximum tumour dimension at baseline is associated with event-free survival in PET negative patients with stage IA/IIA Hodgkin Lymphoma in the UK NCRI RAPID trial
Illidge T, Phillips E, Counsell N, Pettengell R, Johnson P, Culligan D, Popova B, Clifton-Hadley L, McMillan A, Hoskin P, Barrington S, Radford J

Q T014 (0118)

Multicentric Italian experience in treatment of nodular lymphocyte predominant Hodgkin Lymphoma (NLPHL) in the Rituximab era
Gotti M, Sciarra R, Pulsoni A, Merli F, Rusconi C, Botto B, Re A, Rossi A, Rigacci L, Fabbri A, Liberati M, Merli M, Nassi L, Carlo Stella C, Bonfichi M, Zoboli V, Tartaglia G, Alvarez I, Meli E, Nicolosi M, Dalceggio D, Ferrari S, Puccini B, Cencini E, Apolloni V, Ferrario A, Deambrogi C, Ricci F, Avital W, Ferretti V, Arcaini L

Q T015 (0124)

Brentuximab Vedotin and AVD chemotherapy followed by reduced dose/volume radiotherapy in patients with early stage, unfavorable Hodgkin Lymphoma

Yang JC, Kumar A, Casulo C, Advani R, Budde E, Barr PM, Batlevi CL, Caron P, Chen R, Constine LS, Courtien A, Dandapani SV, Drullinsky P, Friedberg JW, Hamilton A, Hamlin PA, Hoppe RT, Horwitz SM, Intlekofer A, Lahoud O, Matasar MJ, Moskowitz AJ, Noy A, Palomba ML, Portlock CS, Schöder H, Straus DJ, Vardhana S, Vemuri S, Younes A, Zelenetz AD, Zhang Z, Yahalom J, Moskowitz CH

Poster Pitch**🕒 P027 (0101)**

Cardiovascular radiation dosimetry and predicted cardiovascular risks from involved field radiotherapy within the UK 'RAPID' trial in early low-risk Hodgkin Lymphoma

Cutter DJ, Ramroth J, Diez P, Buckle A, Kennedy D, Popova B, Clifton-Hadley L, Illidge T, Darby SC, Radford J

🕒 P029 (0142)

Quality assurance of involved-node radiotherapy: first results of the HD17-trial of the GHSG

Kriz J, Baues C, Oertel M, Engenhardt-Cabillic R, Herfarth K, Lukas P, Marnitz-Schulze S, Schmidberger H, Vordermark D, Haverkamp U, Engert A, Eich HT

Posters**P023 (0003)**

Conventional vs multifractionation at radiotherapy for above diaphragm stage II Hodgkin Lymphoma: 30-year experience of single center

Ilyin NV, Vinogradova JN, Ivanova EI

P024 (0009)

Limited-stage Hodgkin Lymphoma: minimizing toxicity

Straus, DJ

P025 (0033)

Metabolic tumor volume by positron emission tomography/computed tomography for deciding the therapeutic modality in patients with early stage Hodgkin's Lymphoma

Chung JS, Song MG, Kim DY, Shin HJ, Kim SJ, Joo YD

P026 (0057)

Interim- PET results for prognosis in adults with Hodgkin Lymphoma: a prognostic factor exemplar review (preliminary results)

Aldin A, Trivella M, Estcourt LJ, Collins G, Moons K, Engert A, von Tresckow B, Kobe C, Foroutan F, Kreuzberger N, Skoetz N

P028 (0102)

Patterns of relapse in patients treated for early stage classical Hodgkin Lymphoma in the modern era

Nielsen K, Maraldo MV, Berthelsen AK, Loft A, Petersen PM, Aznar MC, Vogelius IR, Brown P, Specht L

P030 (0143)

Once-a-cycle vs. daily G-CSF in early-unfavorable stages of Hodgkin Lymphoma treated with BEACOPP escalated followed by ABVD

Fuchs M, Müller H, Eichenauer DA, Kreissl S, Engert A, Borchmann P

P031 (0145)

Evaluation of CCL17 (TARC) as a diagnostic biomarker for classical Hodgkin Lymphoma: interim results from the CANDEL study

Lake A, Nixon IJ, Beattie P, Ah-See K, Culligan D, Heaney N, McKay P, Hilmi OJ, Jarrett RF

Session 5: Survivorship and Patients' Perspective

Talk

Q T016 (0018)

Employment situation among long-term Hodgkin Lymphoma survivors in Europe: an analysis of patients from nine consecutive EORTC-LYSA trials

Maraldo MV, Kicinski M, van der Kaaij MAE, Giusti F, Meijnders P, Aleman BMP, Raemaekers JMM, Moser EC, Kluin-Nelemans HC, Spina M, Fermé C, Brice P, Casasnovas O, Stamatoullas A, André M, Le Bras F, Fortpied C, Bogaerts J, Henry-Amar M, Liu L

Q T017 (0044)

Is routine laboratory testing useful in detecting relapse in patients with classic Hodgkin Lymphoma in first remission?
Lynch RC, Sundaram V, Desai M, Henry S, Wood D, Daadi SE, Corbelli K, Rosenberg SA, Hoppe RT, Advani RH

Q T018 (0140)

Contemporarily treated Hodgkin Lymphoma patients have childbearing potential in line with matched comparators
Weibull CE, Johansson ALV, Eloranta S, Smedby KE, Björkholm M, Lambert PC, Dickman PW, Glimelius I

Poster Pitch

🕒 P036 (0023)

Early-stage Hodgkin Lymphoma (HL) in the modern era: harnessing simulation modeling to delineate long-term patient outcomes

Parsons SK, Kelly MJ, Cohen JT, Castellino SM, Henderson TO, Kelly KM, Keller FG, Henzer TJ, Kumar AJ, Johnson P, Meyer RM, Radford J, Raemaekers J, Hodgson DC, Evens AM

🕒 P060 (0122)

The reciprocal relation between cancer-related fatigue and physical and psychosocial functioning in survivors of Hodgkin lymphoma

Mayer A, Stadtbäumer N, Kreissl S, Müller H, Görgen H, Borchmann P

Posters

P032 (0002)

Audit of lymphoma patient group irradiated blood product policy compliance at a UK comprehensive cancer centre
Gibson J, Wells S, Jackson S, Higham P, Seal D, Linton K

P033 (0007)

Single center analysis of nodular lymphocyte predominant Hodgkin Lymphoma: focus on R-ABVD and interim PET
Visentin A, Pravato S, Scomazzon E, Imbergamo S, Branca A, Gregianin M, Vio S, Boso C, Piazza F, Vianello F, Zambello R, Semenzato G, Trentin L

P034 (0021)

Returning to school or work after Hodgkin Lymphoma: An EORTC-LYSA cross-sectional study
Maraldo MV, Kicinski M, van der Kaaij MAE, Giusti F, Meijnders P, Aleman BMP, Raemaekers JMM, Moser EC, Kluin-Nelemans HC, Spina M, Fermé C, Brice P, Casasnovas O, Stamatoullas A, André M, Le Bras F, Fortpied C, Bogaerts J, Henry-Amar M, Liu L

P035 (0022)

Fatigue impairment in Hodgkin and non-Hodgkin Lymphoma survivors: a joint EORTC-LYSA cross-sectional survey
Mounier N, Busson R, van der Kaaij M, Thieblemont C, Aleman B, Stamatoullas A, Raemaekers J, Ribrag V, Spina M, Tilly H, Fermé C, Haioun C, Casasnovas O, Kluin-Nelemans H, Henry-Amar M

P037 (0027)

The pathway to diagnosis of Hodgkin Lymphoma in South Africa: the determinants and impact of diagnostic delay

Antel K, Levetan C, Mohamed Z, Louw VJ, Oosthuizen J, Verburgh E

P0038 (0029)

Hepatitis B virus infection is not associated with poor prognosis in Hodgkin Lymphoma patients: a case-control study

Liu W, Yang M, Wu M, Ping L, Song Y, Zhu J

P039 (0030)

Temporal trends in treatment-related incidence of diseases of the circulatory system among Hodgkin Lymphoma patients

Weibull CE, Björkholm M, Glimelius I, Lambert PC, Andersson TML, Smedby KE, Dickman PW, Eloranta S

P040 (0031)

Clinicopathological features and prognosis of 387 cases with classical Hodgkin Lymphoma from China

Zhu J, Yang M, Wu M, Ping L, Aliya, Liu Y, Nuersulitan R, Song Y

P041 (0034)

A study of patient and general practitioner (GP) views and experience of managed local follow-up of long term lymphoma survivors (ADAPT)

Taylor S, Goode V, White E, Cowan R, Yorke J, Radford J

P042 (0035)

Anemia has a negative impact on the outcome of patients with Hodgkin Lymphoma

Liu W, Yang M, Wu M, Ping L, Wang X, Song Y, Zhu J

P043 (0039)

Clinical characteristics and prognostic factors of primary extranodal classical Hodgkin Lymphoma: a retrospective study of 27 cases

Zhu J, Yang M, Wu M, Ping L, Aliya, Liu Y, Nuersulitan R, Song Y

P044 (0046)

Investigation the role of adding a serum biomarker to interim PET/CT in Hodgkin Lymphoma patients

Jóna A, Husi K, Nagy B, Fejes Z, Miltényi Z, Illés A

P045 (0047)

Hyperlipoproteinemia and markers of atherosclerosis progression in long-term survivors of Hodgkin Lymphoma in childhood or adolescence and in healthy controls

Cepelova M, Kruseova J, Luks A, Cepela P, Potockova J, Kraml P

P046 (0052)

No clinical signals of drug – drug interaction of NEPA (netupitant + palonosetron) in cHL patients receiving ABVD regimen: a single-center real life experience

Zilioli VR, Minga P, Crucitti L, Meli E, Rusconi C, Cairolì R

P047 (0058)

An epidemiological study of Hodgkins Lymphoma from a single tertiary care centre in India with study of disease outcome

Sen A, Dolai TK, Baul SN, Mandal PK, De R, Dutta S, Chakrabarti P

P048 (0065)

Mature oocytes cryopreservation: a feasible fertility preservation technique in adult Hodgkin Lymphoma female patients

Viviani S, Somigliana E, Filippi F, Landi F, Paffoni A, Mangili G, Mazza R, Papaleo E, Sigismondi C, Devizzi L, Doderò A, Farina L, Corradini P

P049 (0072)

Results of cardiovascular screening in the BETER survivorship care initiative for Hodgkin Lymphoma

Pereboom SR, Nijdam A, Aleman BMP, van der Maazen RWM, Zijlstra JM, de Weijer RJ, van 't Veer MB, Raemaekers JMM, van Leeuwen FE, on behalf of the BETER consortium

P050 (0075)

Clinical characteristics and prognosis analysis of early-stage classical Hodgkin Lymphoma

Zhu J, Liu Y, Wu M, Yang M, Aliya, Rnuersulitan R, Song Y

P051 (0080)

Cardiovascular disease risk after treatment-induced premature ovarian insufficiency in female survivors of Hodgkin Lymphoma

Aleman BMP, Krul IM, Opstal-van Winden AWJ, Janus CPM, Daniëls LA, Appelman Y, Maas AHEM, van Nimwegen FA, de Vries S, Hauptmann M, Józwiak K, van Leeuwen FE

P052 (0082)

Combined prognostic role of biomarkers and PET/CT in patients with Hodgkin Lymphoma

Husi K, Illés A, Nagy B, Fejes Z, Bedekovics J, Miltényi Z

P053 (0091)

Neutrophil to lymphocyte ratio predicts overall survival in newly diagnosed Hodgkin Lymphoma patients – single centre experience

Hajder J, Stanisavljević N, Marisavljević D, Jurišić V, Marković O, Živković R

P054 (0092)

Pregnancy in patients in complete remission after Hodgkin Lymphoma: clinical features and outcome

Gaudio F, Nardelli C, Perrone T, Laddaga FE, Specchia G

P055 (0096)

Health-related quality of life (HRQL) trajectories during treatment for advanced stage pediatric Hodgkin Lymphoma (HL)

Rodday AM, Parsons SK, Bush R, Pei Q, Curtis R, Keller F, Kelly K, Henderson T, Castellino SM

P056 (0097)

Cognitive dysfunction after treatment for Hodgkin Lymphoma

Magyari F, Ivánka T, Égerházi A, Simon Z, Miltényi Z, Kósa K, Illés A

P057 (0108)

Cognitive impairments in patients with Hodgkin's Lymphoma
Vinokurova EG, Marchenko AA, Khrushchev SO, Olexenko LV, Rupchev GE, Vybornykh DE, Moiseeva TN

P058 (0109)

Fertility in Hodgkin's Lymphoma patients after initial therapy at Santa Casa de São Paulo Medical School

Simões MFE, Silva GF, da Cunha Fischer TR, Chiattonne CS, Fortier SC, da Silveira da Rocha, TM

P059 (0114)

AA amyloidosis causing nephrotic syndrome in two patients with Hodgkin Lymphoma

Salihoglu A, Elverdi T, Keskin D, Eskazan AE, Ar MC, Ongoren S, Tuzuner N, Soysal T, Baslar Z

P061 (0125)

Chemotherapy-induced polyneuropathy in patients with Hodgkin Lymphoma treated with vinca-alkaloids

Smardova L, Vlckova E, Rajdova A, Raputova J, Bednarik J, Kral Z

P062 (0134)

Long term health care use in relapsed and non-relapsed paediatric and young adult Hodgkin Lymphoma patients – a population-based cohort study from Sweden and Denmark
Glimelius I, Englund A, Rostgaard K, Smedby KE, Eloranta S, de Nully Brown P, Johansen C, Kamper P, Ljungman G, Hjalgrim LL, Hjalgrim H

P063 (0144)

Cognitive impairment, structural and functional brain morphological sequelae of Hodgkin Lymphoma treatment.

First interim results of ongoing translational study
Kozak T, Horacek J, Mocikova H, Gaherova L, Fayette D, Geislerova L, Karlova I, Markova J

P064 (0146)

Cause-specific mortality among Hodgkin Lymphoma survivors up to 35 years after treatment

de Vries S, Schaapveld M, Lugtenburg PJ, Daniëls LA, Petersen EJ, Zijlstra JM, van Imhoff GW, van der Maazen RWM, Beijert M, van Eggermond AM, Kremer LCM, Louwman MWJ, Lybeert M, de Boer JP, Aleman BMP, van Leeuwen FE

P065 (0150)

Elevated neutrophil-to-monocyte ratio is associated with decreased overall survival at 5 years in classic Hodgkin Lymphoma

Neves D, Roque A, Afonso C, Pinto A, Mota D, Guilherme R, Gomes M, Ribeiro L

P066 (0154)

eBEACOPP for front-line treatment of patients with classical Hodgkin Lymphoma (cHL) in the real world setting

Basic-Kinda S, Dujmovic D, Radman I, Moric-Peric M, Hude I, Durakovic N, Vodanovic M, Dobrenic M, Kralik M, Galunic-Bilic L, Dotlic S, Aurer I

P067 (0166)

Very late relapses (VLRs) in Hodgkin Lymphoma (HL) occurring ≥ 5 years after initial treatment with chemotherapy \pm radiotherapy (CT \pm RT): Pattern of risk over 35 years and the significance of histology

Vassilakopoulos TP, Angelopoulou MK, Kravariti E, Dimopoulou MN, Siakantaris MP, Liaskas A, Gainaru G, Assimakopoulos I, Arapaki M, Diamantopoulos P, Konstantinou I, Boutsikas G, Petevi K, Kanellopoulos A, Giannikos T, Chatzidimitriou C, Efstathopoulou M, Dimou M, Moschogiannis M, Giakoumis X, Pessach I, Sachanas S, Iliakis T, Maltezas D, Kalpadakis C, Komninaka V, Tsaftaris P, Plata E, Kyrtsonis MC, Panagiotidis P, Variami E, Viniou NA, Konstantopoulos K, Pangalis GA

Session 6: Advanced Stages**Talk****Q T019 (0026)**

Potential impact of consolidation radiation therapy for advanced Hodgkin Lymphoma: a secondary modeling analysis of SWOG S0816

Ha CS, Li H, Schoder H, Pinnix C, Brem E, Bartlett N, Evens A, Hsi E, Rimsza L, Leonard JP, Kahl BS, LeBlanc M, Smith S, Constine L, Friedberg JW

Q T020 (0067)

Baseline PET features as predictors of outcome in advanced HL : A prospective evaluation of UK patients in the RATHL trial (CRUK/07/033)

Guezennec C, Kirkwood AA, Pike LC, Patrick P, Burton C, Miall F, Stevens L, Clifton-Hadley L, Radford J, Johnson PW, Barrington SF

Q T021 (0147)

B-CAP (brentuximab vedotin, cyclophosphamide, doxorubicin and prednisolone) in older patients with advanced-stage Hodgkin Lymphoma: results of a phase II intergroup trial by the German Hodgkin Study Group (GHSg) and the Nordic Lymphoma Group (NLG)

Fosså A, Böll B, Goergen H, Kamper P, Leppä S, Molin D, Meissner J, Ritter E, Haaber J, Hutchings M, Fuchs M, Engert A, Kobe C, Borchmann P, on behalf of the German Hodgkin Study Group and the Nordic Lymphoma Group

Posters**P068 (0008)**

JUNB, DUSP2, SGK1, CREBBP and SOCS1 are frequently mutated in T-cell / histiocyte rich large B-cell lymphoma

Schuhmacher B, Bein J, Rausch T, Benes V, Tousseyn T, Vornanen M, Ponzoni M, Gascoyne R, Steidl C, Küppers R, Hansmann ML, Hartmann S

P069 (0013)

Evaluation of clinical characteristics in patients with interim-PET negative but positive end of treatment PET. Data from the prospective HD08-01 FIL study

Rigacci L, Puccini B, Broccoli A, Evangelista A, Gioia D, Dona M, Kovalchuk S, Santoro A, Bonfichi M, Re A, Pagani C, Mannelli L, Zaja F, Vitolo U, Spina M, Pulsoni A, Nassi L, Stelitano C, Salvi F, Rusconi C, Tani M, Freilone R, Borsatti E, Zinzani PL.

P070 (0016)

HIV-associated Hodgkin Lymphoma at Groote Schuur Hospital, Cape Town, South Africa

Opie J, Swart L, Novitzky N

P071 (0024)

A multicenter phase 2 study of sequential brentuximab vedotin and AVD chemotherapy for older patients with untreated classical Hodgkin Lymphoma

Evens AM, Advani RH, Helenowsk I, Fanale M, Smith SM, Jovanovic B, Bociek GR, Klein AK, Winter JN, Gordon LI, Hamlin PA

P072 (0038)

Frontline brentuximab vedotin plus chemotherapy exhibits superior modified progression-free survival vs chemotherapy alone in patients with stage III or IV Hodgkin Lymphoma: phase 3 Echelon-1 study

Radford J, Gallamini A, Jurczak W, Straus DJ, Ansell SM, Kim WS, Younes A, Alekseev S, Illés A, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Heo DS, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin H, Huebner D, Connors JM

P073 (0045)

BEACOPP escalated increases progression free survival in advanced classic Hodgkin Lymphoma – a single centre real life experience

Roque A, Afonso C, Neves D, Pinto A, Mota D, Guilherme R, Gomes M, Ribeiro L

P074 (0049)

Accuracy of PET-based bone marrow assessment in patients with Hodgkin Lymphoma: results from the German Hodgkin Study Group trials HD16, HD17, and HD18

Voltin CA, Goergen H, Baues C, Fuchs M, Mettler J, Kreissl S, Oertl J, Klaeser B, Moccia A, Drzezga A, Engert A, Borchmann P, Dietlein M, Kobe C

P075 (0055)

Should a bulky mediastinal mass larger than 7cm be considered an adverse prognostic factor in patients with advanced Hodgkin Lymphoma and negative interim PET/CT?

Lopez-Alonso R, Mashiach T, Barzilai E, Weiler-Sagie M, Dann EJ

P076 (0056)

Clinical characteristics and treatment outcome of nodular lymphocyte predominant Hodgkin's Lymphoma with THRLBCL-like patterns

Dorokhina EI, Moiseeva TN, Kovrigina AM, Shupletsova IA, Al-Radi LS, Mangasarova YK, Goryacheva SR

P077 (0060)

Comparison immunoarchitectural patterns of primary, extranodal and bone marrow lesions in nodular lymphocyte predominant Hodgkin Lymphoma

Shupletsova I, Kovrigina A, Moiseeva T, Dorokhina E

P078 (0062)

Two distinct prognostic groups in advanced-stage Hodgkin Lymphoma revealed by the presence and site of bulky disease

Qi S, Milgrom S, Dabaja B, Tsang R, Levis M, Ricardi U, Dann EJ, Lopez-Alonso R, Ng A, Yahalom J

P079 (0070)

German evidence-based guideline update on diagnosis, therapy and follow-up of adult Hodgkin Lymphoma patients

Jakob T, Follmann M, Borchmann P, Baues C, Sasse S, Bröckelmann PJ, Kreissl S, Eichenauer DA, von Tresckow B, Bürkle C, Engert A, Skoetz N

P080 (0071)

Analysis of outcomes and prognostic factors of 165 newly diagnosed patients with advanced classical Hodgkin Lymphoma
Zhu J, Aliya, Wu M, Yang M, Liu Y, Nuersulitan R, Song Y

P081 (0084)

A clinicopathologic consensus study of gray zone Lymphoma (GZL) with features intermediate between diffuse large B-cell lymphoma (DLBCL) and classical HL (cHL)

Pilichowska M, Pittaluga S, Ferry JA, Hemminger J, Chang H, Kanakry JA, Sehn LH, Feldman T, Abramson JS, Kritharis A, Hernandez-Ilizaliturri FJ, Lossos IS, Press OW, Fenske TS, Friedberg JW, Vose JM, Blum KA, Jagadeesh D, Woda B, Gupta GK, Gascoyne RD, Jaffe ES, Evens AM

P082 (0087)

Clinical significance of autoimmune hemolytic anaemia and autoimmune thrombocytopenia during the course of Hodgkin Lymphoma

Pinczés L, Miltényi Z, Jóna A, Illés A

P083 (0093)

Low-dose consolidative mediastinal irradiation in accelerated hyperfractionated regimen for advanced Hodgkin Lymphoma

Bogatyeva TI, Pavlov VV, Terekhova AY, Shklyayev SS, Falaleeva NA

P084 (0094)

Brentuximab vedotin and bendamustine as first-line treatment of Hodgkin Lymphoma in the elderly (HALO trial)

Gallamini A, Schiano de Colella JM, Viotti J, Bijou F, Rambaldi A, Perrot A, Patti C, Gastaud L, Sorasio R, Debaigt C, Schiappa R, Chamorey E, Viviani S, Thyss A

P085 (0112)

Treatment toxicity in elderly Hodgkin Lymphoma patients with advanced stage – multicenter retrospective data analysis from the Czech Republic

Sykorova A, Mocikova H, Lukasova M, Koren J, Stepankova P, Prochazka V, Belada D, Klaskova K, Gaherova L, Chroust K, Buresova L, Markova J, on behalf of the Czech Hodgkin Lymphoma Group

P086 (0129)

Metabolic tumour volume for response prediction in advanced-stage Hodgkin Lymphoma

Mettler J, Müller H, Voltin CA, Baues C, Klaeser B, Moccia A, Borchmann P, Engert A, Kuhnert G, Drzezga A, Dietlein M, Kobe C

P087 (0135)

Hodgkin Lymphoma in HIV-positive patients: a single institution retrospective study

Ammoni LC, Fasola C, De Francesco D, Micheli V, Bombonati G, Cattaneo MT, De Troia B, Ferrario S, Filipazzi V, Gambaro AR, Isabella L, Somma L, Tosca N and Dalu D

P088 (0136)

Brentuximab vedotin plus chemotherapy in patients with high-risk advanced-stage classical Hodgkin Lymphoma (cHL): results of prespecified sub-group analyses from the Echelon-1 study

Hutchings M, Radford J, Gallamini A, Illes A, Sureda A, Connors JM, Sykorova A, Shibayama H, Abramson JS, Chua N, Friedberg JW, Koren J, LaCasce AS, Molina L, Josephson N, Song E, Jolin H, Liu R, Gautam A, Ansell S

P089 (0137)

Population pharmacokinetic (POP PK) modeling and exposure-response (ER) assessment of brentuximab vedotin efficacy and safety in patients with advanced classical Hodgkin Lymphoma (cHL) from the phase 3 Echelon-1 study

Suri A, Mould DR, Song G, Collins G, Endres C, Gomez-Navarro J, Venkatakrishnan K

P090 (0141)

PET-CT as a prognostic factor in patients with advanced stages in primary diagnosed Hodgkin Lymphoma (HL)

Pastushenko I, Skrypets T, Novosad O, Kadnikova T, Ashykhmin A, Kmetyuk Y, Karpova O, Mykhalska L, Kozlov V, Novikov N, Oliinichenko E, Kostiukova N, Tkachenko O, Karnabeda O, Stratienco V, Kriachok I

P091 (0159)

Serum sCD30 and TARC do not correlate with PET-based response assessment in patients (pts) with stage III or IV classical Hodgkin Lymphoma (cHL): phase 3 Echelon-1 study of brentuximab vedotin plus chemotherapy vs chemotherapy alone
Sureda A, Connors JM, Younes A, Gallamini A, Ansell SM, Kim WS, Miall F, Bajel A, Knopinska-Postuszny W, Ogden CA, Kuroda S, Liu R, Trepicchio WL, Radford J

Session 7: Pediatric Hodgkin Lymphoma**Talk****Q T022 (0042)**

Survival by race/ethnicity in pediatric and adolescent patients with Hodgkin Lymphoma: a pooled analysis of contemporary Children's Oncology Group trials
Kahn JM, Kelly KM, Pei Q, Friedman DL, Keller F, Bush R, Bhatia S, Henderson TO, Schwartz CL, Castellino SM

Q T023 (0106)

Safety and early response to the first 2 cycles of Brentuximab Vedotin substituting vincristine in the OEPA/COPDAC regimen for high risk pediatric Hodgkin Lymphoma (HL)
Metzger ML, Flerlage J, Krasin M, Bartelt JM, Billett A, Choi JK, Ehrhardt M, Georgi T, Hasenclever D, Hudson M, Kaste SC, Kluge R, Körholz D, Kurch L, Link M, Stoevesandt D, Mauz-Körholz C

Q T024 (0123)

The feasibility of deep inspiration breath-hold in children: results of the TEDDI pilot study
Lundgaard AY, Josipovic M, Rechner L, Bidstrup PE, Hansen R, Damkjaer SS, Joergensen M, Safwat A, Specht L, Hjalgrim L, Maraldo MV

Posters**P092 (0019)**

Proteomic identification of plasma biomarkers in children and adolescents with recurrent Hodgkin Lymphoma
Repetto O, Mussolin L, Elia C, Martina L, Bianchi M, Buffardi S, Sala A, Burnelli R, Mascarin M, De Re V

P093 (0028)

HOPE to COPE with OPPA/COPP: experience of GPOH HD-2002 study protocol in pediatric Hodgkin Lymphoma in a tertiary care hospital in a resource constraint setting
Patra PC, Phukan A, Chakrabarti P, Mandal PK, Dolai TK, De R, Baul S

P094 (0059)

KEYNOTE-667: phase 2, open-label study of pembrolizumab in children and young adults with newly diagnosed classical Hodgkin Lymphoma (cHL) with slow early response (SER) to frontline chemotherapy
Mauz-Körholz C, Kelly K, Keller F, Nahar A, Balakumaran A, Giulino-Roth L

P095 (0064)

Hodgkin's Lymphoma in adolescents: the Italian Association of Pediatric Hematology and Oncology (AIEOP) experience
Burnelli R, Fiumana G, Pillon M, Sala A, Buffardi S, Vinti L, Zecca M, Garaventa A, Rondelli R, Muggeo P, Provenzi M, Farruggia P, Rossi F, Facchini E, Mascarin M, on behalf of the Italian Association of Pediatric Hematology and Oncology

P096 (0085)

M1 macrophage polarization prevails in pediatric Hodgkin Lymphoma from Argentina regardless of Epstein Barr virus presence
Jimenez O, Barros MH, Cohen M, De Matteo E, Garcia Lombardi M, Preciado MV, Niedobitek G, Chabay P

P097 (0105)

Implementing an effective pre-accrual quality assurance programme in the UK to ensure accuracy and consistency of radiotherapy contouring for paediatric Hodgkin's Lymphoma within the EuroNet-PHL-C2 trial (EudraCT 2012-004053-88)
Díez P, Gallop-Evans E, Cutter DJ, Chang YC, Sivabalasingham S, Ajithkumar T, Hedegaard DL, Hayward J, Daw S

P098 (0111)

Treatment outcomes of adolescent and young adult (AYA) Hodgkin Lymphomas (HL): real world data from a tertiary care cancer centre
Sengar M, Jain H, Epari S, Laskar S, Bagal B, Shet T, Gujral S, Agrawal A, Rangarajan V, Gokarn A, Khanna N, Goda JS, Pawaskar P, Chanana R

P099 (0117)

Survival by age in children and adolescents with Hodgkin Lymphoma: a pooled analysis of Children's Oncology Group (COG) trials
Kahn JM, Kelly KM, Pei Q, Friedman DL, Keller F, Bush R, Bhatia S, Henderson TO, Schwartz CL, Castellino SM

P100 (0119)

FAMHL: genetic study of families with a high frequency of classical Hodgkin Lymphoma
Flerlage JE, Goldin L, McMaster ML, Mullighan C, Nichols K, Kesserwan C, Hamilton K, Maciaszek J, Rampersaud E, Wu G, Qian M, Williams M, Metzger ML, Yang JJ

P101 (0149)

Phase 1/2 study of brentuximab vedotin plus AVD in pediatric patients with advanced stage newly diagnosed classical Hodgkin lymphoma
Franklin A, Zecca M, Luisi FA, Song G, Suri A, Leonard EJ, Locatelli F

P102 (0151)

Durable remission for two patients with early relapse of Hodgkin Lymphoma, treated with brentuximab vedotin plus Gemcitabine, without autologous stem cell transplantation: a report from the Children's Oncology Group
Buhtoiarov I, Mba N, De Los Santos C, McCarten KM, Metzger ML, Pei Q, Bush R, Kelly KM, Flagg A, Hanna R, Cole P

P103 (0152)

Stanford V chemotherapy and low dose radiotherapy for children and adolescents with unfavorable and intermediate risk Hodgkin Lymphoma: results of a multi-institutional prospective clinical trial
Metzger ML, Billett AL, Friedmann AM, Krasin MJ, Weinstein HJ, Larsen EC, Marcus KJ, Li C, Lu Z, Donaldson SS, Link MP, Hudson MM

Session 8: Immunotherapy – Clinical**Talk****Q T025 (0005)**

Brentuximab Vedotin in combination with Nivolumab in patients with relapsed or refractory Hodgkin Lymphoma: follow-up results from the phase 1/2 study
Herrera AF, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, LaCasce AS, Ansell SM, Moskowitz CH, Fenton K, Sacchi M, Galderisi F, Advani RH

Q T026 (0025)

A phase II study of SHR-1210, an anti-PD-1 antibody, in Chinese patients with relapsed/refractory classic Hodgkin Lymphoma
Zhu J, Feng J, Chen X, Lin T, Cao J, Liu Y, Zhao Y, Jin J, Huang H, Hu J, Luo J, Zhang L, Xue H, Zhang Q, Yao Y

Q T027 (0153)

Phase 2 Study of Frontline Brentuximab Vedotin Plus Nivolumab in Patients with Hodgkin Lymphoma Aged ≥ 60 Years
Friedberg JW, Yassenchak CA, D'Amato G, Holkova B, Patel-Donnelly D, Anderson T, Larson T, Wang Y, Galderisi F, Chen R

Q T028 (0163)

Allogeneic stem cell transplantation (allo-SCT) for relapsed/refractory classical Hodgkin Lymphoma (cHL) patients treated with Nivolumab is associated with an unprecedented low relapse rate
Castagna L, Magagnoli M, Mazza R, Morello L, Ricci F, Bramanti S, Sarina B, Mariotti J, De Philippis C, Sica S, Rodari M, Sollini M, Kirienko M, Chiti A, Santoro A, Carlo-Stella C

Poster Pitch**🕒 P105 (0032)**

A phase II study of pembrolizumab (pem) followed by AVD for frontline treatment of classical Hodgkin Lymphoma (cHL): interim results
Allen PB, Evens AM, Pro B, Karmali R, Savas H, Dillehay G, Rademaker A, Palmer B, Advani R, Gordon LI, Winter JN

Posters**P104 (0004)**

Nivolumab in relapsed/refractory classic Hodgkin Lymphoma: Experience with ten patients
Dada R, Zabani Y

P106 (0131)

Clinical benefit of Nivolumab in Hodgkin Lymphoma but at what price? Example into a Paris University Hospital
Peyrilles E, Madelaine I, Thieblemont C, Brice P

P107 (0155)

Pembrolizumab monotherapy in relapsed/refractory classic Hodgkin Lymphoma: updated efficacy and safety analysis of the phase 2 KEYNOTE-087 study
Zinzani PL, Chen R, Armand P, Johnson N, Brice P, Radford R, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, Von Tresckow B, Shipp MA, Kim E, Nahar A, Balakumaran A, Moskowitz CH

Session 9: Relapsed/Refractory HL**Talk****Q T029 (0010)**

Second autologous stem cell transplantation (ASCT) for relapsed or refractory (r/r) Hodgkin Lymphoma (HL) after a previous autograft: a registry study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation
Martínez C, Boumendil A, Romejko-Jarosinska J, Anagnostopoulos A, Faber E, Poiré X, Yakoub-Agha I, Akhtar S, Gurman G, Pavone V, Halaburda K, Sousa AB, Salles G, Finel H, Khvedelidze I, Montoto S, Sureda A

Q T030 (0103)

Bendamustine, gemcitabine, and dexamethasone (BGD) chemotherapy followed by autologous stem cell transplantation (ASCT) is effective treatment for patients with relapsed/refractory Hodgkin Lymphoma (rHL) – Results of the Polish Lymphoma Research Group (PLRG) pilot study – Pre-PLRG-HL1 (BURGUND)
Paszkiwicz-Kozik E, Tyczynska A, Kotarska M, Szymanski M, Targonski L, Drozd-Sokolowska J, Rybka J, Wojciechowska-Lampka E, Tajer J, Poplawska L, Romejko-Jarosinska J, Osowiecki M, Rybski S, Zaucha J, Walewski J

Q T031 (0110)

Five-year progression-free survival outcomes from a pivotal phase 3 study of consolidative Brentuximab Vedotin after autologous stem cell transplant in patients with Hodgkin Lymphoma at risk of relapse or progression (AETHERA)
Moskowitz CH, Walewski J, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Viviani S, Bachanova V, Sureda A, McClendon T, Lee C, Lisano J, Sweetenham J

Q T032 (0130)

Relapse after early-stage favorable Hodgkin Lymphoma: disease characteristics, treatment strategies and their outcome
Bröckelmann PJ, Müller H, Guhl T, Behringer K, Fuchs M, von Tresckow B, Borchmann P, Engert A

P118 (0068)

Long term safety and efficacy of combination of brentuximab vedotin and ipilimumab or nivolumab in relapsed/refractory Hodgkin Lymphoma: a trial of the ECOG-ACRIN Cancer Research Group (E4412)

Diefenbach CS, Hong F, Ambinder RF, Cohen JB, Robertson MJ, David KA, Advani RH, Fenske TS, Barta SK, Palmisano ND, Svoboda J, Morgan DS, Karmali R, Kahl BS, Ansell SM

P126 (0121)

PD-1 blockade for Hodgkin Lymphoma after allogeneic stem cell transplantation

Meissner J, Dietrich S, Sureda A, Finel H, Khvedelidze I, Castagna L, Milpied N, Ghesquieres H, Ram R, Bazarbachi A, Houot R, Maschmeyer G, Russo D, Passweg J, Spyridonidis A, Stadler M, Robinson S, Dreger P, Montoto S

Posters

P108 (0001)

Allogeneic stem cell transplantation after treatment with checkpoint inhibitors: feasibility and safety in pooled analysis
Dada R, Usman B

P109 (0012)

High CR rate in interim results of a phase II trial of Nivolumab with or without ICE in relapsed/refractory HL prior to AHCT
Chen R, Palmer J, Herrera A, Lee H, Tsai N, Song J, McBride K, Mei M, Zain J, Popplewell L, Nademanee A, Rosen S, Kwak L, Forman S

P110 (0014)

Successful treatment of Hodgkin Lymphoma with brentuximab vedotin relapsing after autologous stem cell transplantation
Markova J, Mocikova H, Gaheerova L, Kozak T, on behalf of the Czech Hodgkin Lymphoma Study Group

P111 (0017)

Time to relapse in nodular lymphocyte-predominant Hodgkin Lymphoma is related to the histopathological pattern at initial diagnosis and relapse

Hartmann S, Schuhmacher B, Plütschow A, Bein J, Mottok A, Bernd HW, Feller AC, Ott G, Cogliatti S, Hummel M, Fend F, Quintanilla-Martinez L, Stein H, Klapper W, Möller P, Küppers R, Rosenwald A, Engert A, Hansmann ML, Eichenauer DA

P112 (0020)

A phase II study with bendamustine plus brentuximab vedotin in Hodgkin's Lymphoma in first salvage setting: the BBV regimen
Broccoli A, Botto B, Corradini P, Pinto A, Re A, Cesaretti M, Argnani L, Vitolo U, Zinzani PL

P113 (0040)

Phase I/II study of Brentuximab vedotin in first refractory/relapsed classical Hodgkin Lymphoma patients treated by chemotherapy (ICE) before autologous transplantation
Stamatoullas A, Ghesquieres H, Perrot A, Quittet P, Morschhauser F, Ribrag V, Edeline V, Brice P, for the LYSA group

P114 (0041)

Results of Mini-BEAM as second salvage chemotherapy after DHAP based chemotherapy for relapsed or refractory classical Hodgkin Lymphoma
Veldman C, Nijland M, van Meerten T, Hoogendoorn M, Huls GW, Plattel WJ

P115 (0048)

Brentuximab vedotin (BV) as maintenance or salvage therapy after ASCT for relapsed/refractory (R/R) HL
Milcheva K, Petrov Y, Naseva E, Ganeva P, Ignatova K, Aranaudov G, Spasov B

P116 (0054)

Early transplant related complications in Hodgkin Lymphoma patients receiving PD-1 inhibitors before allogeneic stem cell transplantation
de Philippis C, Mariotti J, Bramanti S, Sarina B, Magagnoli M, Morello L, Santoro A, Carlo-Stella C, Castagna L

P117 (0063)

Bendamustine in heavily pre-treated Hodgkin Lymphoma patients

Pavlov W, Falaleeva NA, Bogatyreva TI, Shklyayev SS, Terekhova AY, Volodina OM

P119 (0078)

Real life data of brentuximab vedotin use in relapsed / refractory HL in Sweden

Jansson C, Lagerlöf I, Linderöth J, Johansson AS, Ellin F, Palma M, Jerlström U, Smedby KE, Molin D

P120 (0086)

Outcomes and toxicities after brentuximab vedotin (BV) maintenance in relapsed/refractory Hodgkin Lymphoma patient exposed to BV prior to autologous hematopoietic stem cell transplant

Shah GL, Moskowitz AJ, Rajvee S, McCall SJ, Maloy MA, Sauter C, Giralto SA, Matasar MJ, Moskowitz CH

P121 (0089)

Sequential time-intensified brentuximab vedotin (BV) followed by gemcitabine, vinorelbine and pegylated liposomal doxorubicin (GVD) as a bridge to autologous transplantation in DHAP resistant relapsed or refractory CD30+ Lymphoma

Cernauskiene S, Semaskeviciene R, Mickeviciute O, Griskevicius L

P122 (0090)

Brentuximab vedotin prior to allogeneic transplantation in Hodgkin's Lymphomas reduces chronic GVHD without worsening the outcome

Gaudio F, Mazza P, Carella AM, Mele A, Palazzo G, Pisapia G, Carluccio P, Pastore D, Cascavilla N, Specchia G, Pavone V

P123 (0107)

Next generation sequencing-based clonality assessment of immunoglobulin gene rearrangements distinguishes relapse from second primary Hodgkin Lymphoma

van Bladel D, van den Brand M, Rijntjes J, Brinkman A, Reigl T, Darzentas N, Hess C, Hebeda K, van Krieken H, Groenen P, Scheijen B

P124 (0115)

Retrospective real-life study of the BEGEV (bendamustine, gemcitabine, vinorelbine) regimen in heavily pretreated, relapsed / refractory classical Hodgkin Lymphoma patients

Russo A, Pulsoni A, Ricci F, Mazza R, Magagnoli M, Morello L, Rodari M, Serrao A, Annechini G, Nervini A, Giordano L, Castagna L, Chiti A, Santoro A, Carlo-Stella C

P125 (0116)

Nivolumab re-treatment in patients with relapsed / refractory Hodgkin Lymphoma

Ansell SM, Armand P, Timmerman JM, Shipp MA, Jäger U, Willenbacher W, Saleem R, He J, Sacchi M, Sumbul A, Lesokhin AM

P127 (0126)

Autologous (auto-HCT) and allogeneic stem cell transplantation (allo-HCT) in the management of relapsed / refractory (RR) Hodgkin Lymphoma (HL). A retrospective analysis of the Lymphoma Working Party of the EBMT

Sureda A, Genadieva-Stavrik S, Boumendil A, Finel H, Khvedelidze I, Dietrich S, Dreger P, Hermine O, Kyriakou C, Robinson S, Schmitz N, Schouten H, Tanase A, Montoto S

P128 (0127)

Successful slow desensitization to brentuximab vedotin after anaphylaxis: 3 case reports in the Basque autonomous community

Otero Longo I, Aranbarri Larrañaga A, Caminos Altuna N, Martinez Molina S, Joral Badas A, Ondarra Seguro I

P129 (0128)

Clinical analysis of relapse patterns in Hodgkin Lymphoma

Oertel M, Kriz J, Kerkhoff A, Reusch J, Kröger K, Elsayad K, Haverkamp U, Lenz G, Eich HT

P130 (0132)

Primary progressive classical Hodgkin Lymphoma – A single centre experience

Afonso C, Roque A, Neves D, Pinto A, Mota D, Guilherme R, Gomes M, Ribeiro L

P131 (0133)

Pooled results of two annual cohorts from an observational prospective study describing brentuximab vedotin use in routine practice in France for Hodgkin Lymphoma: interim analysis
Sibon D, Quittet P, Borel C, Stamatoullas A, Franchi-Rezgui P, Ghesquières H, Dulery R, Benbrahim O, Hammoud M, Filliatre-Clément L, De Guibert S, Coulibaly C, Casasnovas O, Bouabdallah R, Brice P, for ODICE study group

P132 (0138)

Patterns and outcomes with salvage treatment for Hodgkin Lymphoma (HL) in the modern era: a real-world analysis from the community oncology setting in the United States
Kumar AJ, Chao CR, Rodday AM, Cannizzaro NT, Rodriguez R, Feliciano J, Evens AM, Parsons SK

P133 (0148)

Prognostic value of (18) f-fluorodeoxyglucose-positron emission tomography on survival in Hodgkin Lymphoma patients treated with allogeneic stem cell transplantation
Domingo-Domènech E, Martínez C, del Pilar Perlaza M, Cortes M, Gutiérrez G, Parody R, Suárez-Lledó M, Fernández-Avilés F, Sanchez-Ortega I, Rovira M, Setoain X, Ortíz V, Sureda A

P134 (0156)

Induction therapy with everolimus in combination with DHAP (dexamethasone, high-dose arac, cisplatinum) in patients with relapsed or refractory classical Hodgkin Lymphoma: a randomized, placebo-controlled phase I/II trial (HD-R3i)
von Tresckow B, Hüttman A, Vucinic V, Müller H, Pluetschow A, Viardot A, Topp MS, Kobe C, Böll B, Eichenauer DA, Sasse S, Haverkamp H, Fuchs M, Engert A, Borchmann P

P135 (0160)

Brentuximab vedotin + bendamustine: a highly effective salvage treatment on refractory/relapsed patients with Hodgkin Lymphoma
Martineau D, Sauvezie M, Oberic L, Mazari A, Banos A, Bijou F, Brice P, Thyss A, Gac AC, Gyan E, Milpied N, Bouabdallah K

P136 (0161)

Long term outcome of patients with relapsed / refractory Hodgkin Lymphoma treated at a single institution over 25 years
Romejko-Jarosinska J, Paszkiewicz-Kozik E, Tajer J, Wojciechowska-Lampka E, Martyna Kotarska M, Borawska A, Poplawska L, Domanska-Czyz K, Ostrowska B, Osiadacz W, Osowiecki M, Dabrowska-Iwanicka A, Swierkowska M, Targonski L, Szymanski M, Konecki R, Walewski J

P137 (0165)

Treatment strategies and prognostic factors for the outcome of very late relapses (VLRs) occurring ≥ 5 years after initial treatment with chemotherapy \pm radiotherapy (CT \pm RT) in Hodgkin Lymphoma (HL): a joint study from the University of Athens and Istituto Nazionale dei Tumori Milano
Vassilakopoulos TP, Liaskas A, Rizzuto G, Angelopoulou MK, Dimopoulou MN, Mussetti A, Siakantaris MP, Assimakopoulos I, Arapaki M, Korkolopoulou P, Cabras A, Rassidakis G, Dimou M, Variami E, Panagiotidis P, Corradini P, Konstantopoulos K, Pangalis GA, Viviani S

**TPV and AL had equal contribution to this work*

P138 (0167)

Long-term high dose chemotherapy before hematopoietic stem cell transplantation due to restricted access to new therapies
Vanelli T, Rocha G, Brum C, Capra M, Schneider E, Soares T, Fischer G, Contin L, Lodi SF, Botan G, Fogliato L

P139 (0169)

Brentuximab vedotin alone and in combination with bendamustine as salvage therapy for primary refractory or relapsed Hodgkin Lymphoma: multicentre experience of the Polish Lymphoma Research Group
Czyz A, Lojko-Dankowska A, Joks M, Komarnicki M, Dlugosz-Danecka M, Jurczak W, Rybka J, Wrobel T, Paszkiewicz E, Walewski J, Hawrylecka D, Drozd-Sokolowska J, Subocz E, Szymanska A, Witkowska M, Smolewski P, Giebel S, Zaucha JM

Advani, Ranjana: *radvani@stanford.edu*
Allen, Pamela: *pamela.b.allen@emory.edu*
André, Marc: *marc.andre@uclouvain.be*
Ansell, Stephen: *ansell.stephen@mayo.edu*
Armand, Philippe: *Philippe_Armand@dfci.harvard.edu*
Baiocchi, Otavio: *obaiocchi@gmail.com*
Barrington, Sally: *sally.barrington@kcl.ac.uk*
Baues, Christian: *christian.baues@uk-koeln.de*
Böll, Boris: *boris.boell@uk-koeln.de*
Borchmann, Peter: *Peter.Borchmann@uni-koeln.de*
Borchmann, Sven: *sven.borchmann@uk-koeln.de*
Bräuninger, Andreas: *Andreas.Braeuninger@patho.med.uni-giessen.de*
Brice, Pauline: *Pauline.Brice@sls.aphp.fr*
Bröckelmann, Paul J.: *Paul.Broeckelmann@uk-koeln.de*
Casagrande, Naïke: *naïke.casagrande@libero.it*
Casasnovas, Olivier: *olivier.casasnovas@chu-dijon.fr*
Castagna, Luca: *luca.castagna@cancercenter.humanitas.it*
Constine, Louis: *Louis_Constine@urmc.rochester.edu*
Cuccaro, Annarosa: *annarosa.cuccaro@gmail.com*
Dabaja, Bouthaina: *bdabaja@mdanderson.org*
Delfau-Larue, Marie-Hélène: *marie-helene.delfau@hmn.aphp.fr*
Diehl, Volker: *v.diehl@uni-koeln.de*
Dietlein, Markus: *markus.dietlein@uk-koeln.de*
Drees, Esther: *e.drees@vumc.nl*
Eichenauer, Dennis A.: *dennis.eichenauer@uk-koeln.de*
Engert, Andreas: *a.engert@uni-koeln.de*
Evens, Andrew: *ae378@cinj.rutgers.edu*
Fiaccadori, Valeria: *valeria.fiaccadori.17@ucl.ac.uk*
Fosså, Alexander: *aff@ous-hf.no*
Friedberg, Jonathan: *jonathan_friedberg@urmc.rochester.edu*
Gallamini, Andrea: *andrea.gallamini@gmail.com*
Gandhi, Maher K.: *m.gandhi@uq.edu.au*
Gattenlöhner, Stefan: *stefan.gattenloehner@patho.med.uni-giessen.de*
Geissler, Jan: *jan@cmladvocates.net*
Glimelius, Ingrid: *Ingrid.Glimelius@igp.uu.se*
Gotti, Manuel: *manuel.gotti@hotmail.it*
Ha, Chul S.: *hac@uthscsa.edu*

Hagenbeek, Anton: *a.hagenbeek@amc.uva.nl*
Hansmann, Martin-Leo: *m.l.hansmann@em.uni-frankfurt.de*
Hartmann, Sylvia: *s.hartmann@em.uni-frankfurt.de*
Henke, Oliver: *oliver.henke@charite.de*
Herrera, Alex: *aherrera@coh.org*
Hertzberg, Marc: *mhertzberg10@gmail.com*
Hoppe, Richard: *Richard.Hoppe@stanford.edu*
Hutchings, Martin: *hutchings@dadlnet.dk*
Illidge, Tim: *Tim.Illidge@ics.manchester.ac.uk*
Johnson, Peter: *Johnsonp@soton.ac.uk*
Kahn, Justine: *jk2034@cumc.columbia.edu*
Karihtala, Kristiina: *kristiina.karihtala@gmail.com*
Kelly, Kara: *Kara.Kelly@RoswellPark.org*
Kinley, Judith: *judith.kinley@takeda.com*
Klapper, Wolfram: *wklapper@path.uni-kiel.de*
Knoop, Hans: *hans.knoop@amc.uva.nl*
Kobe, Carsten: *carsten.kobe@uk-koeln.de*
Küppers, Ralf: *ralf.kueppers@uk-essen.de*
Lister, Andrew: *a.lister@qmul.ac.uk*
Lollies, Anna: *anna.lollies@uk-essen.de*
Lynch, Ryan: *rclynch@uw.edu*
Maraldo, Maja: *maja.vestmoe.maraldo@regionh.dk*
Marnitz-Schulze, Simone: *simone.marnitz-schulze@uk-koeln.de*
Martínez, Carmen: *cmarti@clinic.ub.es*
Mauz-Körholz, Christine:
christine.mauz-koerholz@paediat.med.uni-giessen.de
Meignan, Michel: *michel.meignan@aphp.fr*
Metzger, Monika: *monika.metzger@stjude.org*
Morton, Lindsay: *mortonli@mail.nih.gov*
Moskowitz, Craig H.: *CHM78@miami.edu*
Mottok, Anja: *anja.mottok@uni-ulm.de*
Parsons, Susan: *sparsons@tuftsmedicalcenter.org*
Paszkievicz-Kozik, Ewa: *epaszkievicz@coi.waw.pl*
Warwick, Lorna: *lorna@lymphomacoalition.org*
Plate, Ananda: *plate@mpeurope.org*
Radford, John: *John.Radford@manchester.ac.uk*
Raemaekers, John: *johnmienraemaekers@gmail.com*
Rassidakis, George: *georgios.rassidakis@ki.se*

Romejko-Jarosinska, Joanna: *jarosinska@coi.waw.pl*
Roschewski, Mark: *mark.roschewski@nih.gov*
Rosenwald, Andreas: *rosenwald@uni-wuerzburg.de*
Rossi, Davide: *davide.rossi@ior.iosi.ch*
Shipp, Margaret: *Margaret_shipp@dfci.harvard.edu*
Song, Yuqin: *songyuqin622@163.com*
Specht, Lena: *specht@rh.dk*
Steidl, Christian: *CSteidl@bccancer.bc.ca*
Sureda, Anna: *asureda@iconcologia.net*
Torres Viera, Maria Alejandra: *matorresviera@gmail.com*
Tucci, Alessandra: *alessandra.tucci@asst-spedalivicivi.it*
van den Berg, Anke: *a.van.den.berg01@umcg.nl*
van Leeuwen, Flora: *f.v.leeuwen@nki.nl*
Visentin, Andrea: *andrea.visentin@aopd.veneto.it*
West, Catharine: *catharine.west@manchester.ac.uk*
Wojnowski, Leszek: *wojnowski@uni-mainz.de*
Yahalom, Joachim: *yahalomj@mskcc.org*
Yang, Jun: *Jun.Yang@STJUDE.ORG*
Yang, Joanna: *joanna.c.yang@gmail.com*
Zinzani, Pier Luigi: *pierluigi.zinzani@unibo.it*



YOUNG INVESTIGATOR AWARD

Annika Weiß | ☉ P019

Valeria Fiacadori | ♀ T012

Nele Stadtbäumer | ☉ P060

Ryan Lynch | ♀ T017

Justine Kahn | ♀ T022

KARL MUSSHOF PRIZE Basic and Translational Science

The Karl Musshoff Foundation was established by Professor Karl Musshoff in 1997. The Karl Musshoff Prize is granted during ISHL in Cologne for outstanding results and a life-long contribution to the field of Hodgkin Lymphoma.

This year's prize in the category "Basic and Translational Science" will be awarded to:

RALF KÜPPERS

KARL MUSSHOF PRIZE Clinical Research

The Karl Musshoff Foundation was established by Professor Karl Musshoff in 1997. The Karl Musshoff Prize is granted during ISHL in Cologne for outstanding results and a life-long contribution to the field of Hodgkin Lymphoma.

This year's prize in the category "Clinical Research" will be awarded to:

RICHARD HOPPE

We would very much like to thank all of our partners for their generous sponsoring.

Name of Sponsor	Total Sponsoring Amount	Sponsoring Benefit
AstraZeneca GmbH	€ 4,000.00	Booth
Bristol-Myers Squibb	€ 52,000.00	Symposium / Booth / Advertisement Final Program
Celgene GmbH	€ 22,500.00	Symposium
Chugai Pharma Europe Ltd.	€ 22,500.00	Symposium
Sandoz Germany	€ 32,000.00	Symposium
Merck & Co., Inc.	€ 8,000.00	Booth
MSD SHARP&DOHME GMBH	€ 32,000.00	Symposium
Mundipharma EDO GmbH	€ 4,000.00	Advertisement
Novartis Pharma GmbH	€ 4,000.00	Booth
Roche Pharma AG	€ 4,000.00	Booth
Sanofi Genzyme GmbH	€ 4,000.00	Booth
Takeda Oncology	€ 80,000.00	2 Symposia / Booth / Advertisement Final Program

FOREFRONT[®]

IN HODGKIN LYMPHOMA

Science. Progress. Care.

Seattle Genetics and Takeda Oncology are leading the way to a better understanding of classical Hodgkin lymphoma by expanding knowledge around the biological development of the disease and the critical role of CD30. By driving science forward, we are helping to address the unanswered questions to improve the treatment of Hodgkin lymphoma.

Our commitment to advancing care for people living with Hodgkin lymphoma is demonstrated by more than 50 clinical trials, including two large, randomized, phase III company-sponsored studies. We take pride in providing unparalleled support for clinical research in Hodgkin lymphoma with the goal of improving outcomes for patients around the world.

Patients are at the center of our mission. We work alongside advocacy groups to improve the patient experience and outcomes by advancing education and identifying and addressing their unmet needs.

Join our journey at the forefront of science, progress, and care by visiting us at our booth at ISHL.

 Seattle Genetics[®]

 Takeda

ONCOLOGY

Takeda Oncology is a business unit of Takeda Pharmaceutical Company Limited
Seattle Genetics and its logo are US registered trademarks of Seattle Genetics, Inc.
©2018 Seattle Genetics, Inc., Bothell, WA 98021, Millennium Pharmaceuticals, Inc., Cambridge, MA
Takeda Oncology and its logo are trademarks of Takeda Pharmaceutical Company Limited.

08/18 GON/NON/15/0050a(2)

OPDIVO[®]
(nivolumab)

**GIVE MORE PATIENTS
THE OPDIVO OPPORTUNITY.**



**OPDIVO[®] – Approved for Relapsed or
Refractory Classical Hodgkin's Lymphoma¹**

OPDIVO as monotherapy is indicated for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplant (ASCT) and treatment with brentuximab vedotin.

German and English Summary of Product Characteristics are available at the booth.


References: 1. OPDIVO[®] Summary of Product Characteristics.

©2018 Bristol-Myers Squibb Company. All rights reserved.
OPDIVO[®] and the related logos are trademarks of Bristol-Myers Squibb Company.

1506DE1804914-01 Date of preparation: August 2018

 **Bristol-Myers Squibb**

GÜRZENICH CONGRESS CENTER



First Level "Großer Saal"

Sat. 27.10.2018	Workshops, Scientific Symposia, Scientific Program, Opening Ceremony
Sun. 28.10.2018	Scientific Program, Scientific Symposia
Mon. 29.10.2018	Scientific Program, Scientific Symposia

First Level "Isabellensaal"

Sat. 27.10.2018	Workshops
Sun./ Mon. 28./ 29.10.2018	Exhibition Hall, Coffee Bar

Ground Floor "Kleiner Saal"

Sat. 27.10.2018	Workshops
Sun. 28.10.2018	Poster Session
Mon. 29.10.2018	Poster Session

Ground Floor "Marsiliussaal"

Sat. 27.10.2018	Workshops
-----------------	-----------

Foyer Ground Floor

Sat.– Mon. 27.–29.10.2018	Registration, Internet, Speakers Ready Room
---------------------------	---

Basement: WC

Sat. 27.10.2018	Welcome Reception
-----------------	-------------------

Dorint Hotel – Martin/Augustin

Sat. 27.10.2018	Workshops
-----------------	-----------

SAVE THE DATE

12th International Symposium on Hodgkin Lymphoma
October 2020

Further information will be available at
www.hodgkinsymposium.org

ISHL 12



**ISHL11
FOR YOUR MOBILE**

Please bookmark URL or use QR-Code
app.ishl.eu